## Annotated Study Book for Study Design: sdGUIDEIT

## Study Design Version: 7.0

## Study Design

## Generated by Central Designer TM

July 15, 2015 11:32AM

Element		Sys	tem																													
Assessment			Enrollment		only (DCRI)	active	Hospitalizations (HOSP) [S/R]	Baseline (BLN) [S]	Baseline follow- up (BLNFU) [S/R]	visits (WKS2)	follow-up	visits	follow-up		3 month follow-up (MON3FU) [S/R]		6 month follow-up (MON6FU) [S/R]		9 month follow-up (MON9FU) [S/R]		12 month follow-up (MON12FU) [S/R]	15 month (MON15) [S]	15 month follow-up (MON15FU) [S/R]		18 month follow-up (MON18FU) [S/R]	21 month (MON21) [S]	21 month follow-up (MON21FU) [S/R]	24 month (MON24) [S]	24 month follow-up (MON24FU) [S/R]	(EOS)	DCRI Imaging (DCRIECHO) [S/R]	Investiga Signatur ) (INVSIG [S]
Visit Start Hours		0	0	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28
System Screening	SYSSCR	1																														
System Enrollment	SYSENR		1																													
RAND	RAND			1																												
Clinical Operations review	CLINOPS				1																											
Clinical Operations review of withdrawn	CLINOPSWD				2																											
CEC manual triggers	CECMT				3-RF																											-
CAS Trigger form	CASTRIG					1																										
Adverse events	AE					2-DF- RF																										
Extended care	EXTCARE					3-DF- RF																										
0 Date of evaluation	DOE						1		1		1		1		1		1		1		1		1		1		1		1		1	
1 Hospitalizations/Emergency Dept visits	HOSP						2																									
2 Acute coronary syndrome	ACS						3-DF																									
3 Hospitalization for heart failure	HF						4-DF																									
4 Subject Demographics	DEM							1																								-
5 Medical History	MEDHX							2																								-
6 Baseline Assessments	BASE							3																								
7 Recent Ejection Fraction	EF							4																								
8 Examination	EXAM							5	2	2-DF	2	2-DF	2	2-DF	2	2-DF	2	2-DF	2	2-DF	2	2-DF	2	2-DF	2	2-DF	2	2-DF	2			
9 Concomitant medications	MEDS							6		4-DF		4-DF		4-DF		4-DF		4-DF		4-DF		4-DF		4-DF		4-DF		4-DF				
0 Local NT-pro-BNP	PROBNP							7	4-DF	5-DF	4-DF	5-DF	4-DF	5-DF	4-DF	5-DF	4-DF	5-DF	4-DF	5-DF	4-DF	5-DF	4-DF	5-DF	4-DF	5-DF	4-DF	5-DF	4-DF			
1 Local Labs	LABS							8-DF	5-DF	6-DF	5-DF	6-DF	5-DF	6-DF	5-DF	6-DF	5-DF	6-DF	5-DF	6-DF	5-DF	6-DF	5-DF	6-DF	5-DF	6-DF	5-DF	6-DF	5-DF			
2 Biobank	BIOBANK							9-DF-RF	7-DF-RF	8-DF-RF	7-DF-RF	8-DF-RF	7-DF-RF	8-DF-RF	7-DF-RF	8-DF-RF	7-DF-RF	8-DF-RF	7-DF-RF	8-DF-RF	7-DF-RF	8-DF-RF	7-DF-RF	8-DF-RF	7-DF-RF	8-DF-RF	7-DF-RF	8-DF-RF	7-DF-RF			
3 Specimen consent	SPECCONS							10																								
4 Therapy Adjustment	ADJUST							11-DF- RF	6-DF-RF	7-DF-RF	6-DF-RF	7-DF-RF	6-DF-RF	7-DF-RF	6-DF-RF	7-DF-RF	6-DF-RF	7-DF-RF	6-DF-RF	7-DF-RF	6-DF-RF	7-DF-RF	6-DF-RF	7-DF-RF	6-DF-RF	7-DF-RF	6-DF-RF	7-DF-RF	6-DF-RF			
5 Adherence Case Review	ACR							12-DF	8-DF	9-DF	8-DF	9-DF	8-DF	9-DF	8-DF	9-DF	8-DF	9-DF	8-DF	9-DF	8-DF	9-DF	8-DF	9-DF	8-DF	9-DF	8-DF	9-DF	8-DF			
6 Adherence Review Findings	ARF							13-DF	9-DF	10-DF	9-DF	10-DF	9-DF	10-DF	9-DF	10-DF	9-DF	10-DF	9-DF	10-DF	9-DF	10-DF	9-DF	10-DF	9-DF	10-DF	9-DF	10-DF	9-DF			
7 Assessments	ASMT								3	3-DF	3	3-DF	3	3-DF	3	3-DF	3	3-DF	3	3-DF	3	3-DF	3	3-DF	3	3-DF	3	3-DF	3			
8 Method of Contact	CONTACT									1		1		1		1		1		1		1		1		1		1				-
9 End of study	EOS											1						1					1			1		1	1	1		
0 Death	DEATH											1					1												1	2-DF		1
1 Echo trigger form	ECHOTRG											1											1			1		1	1		2	
2 FINDINGS	FNDGS							İ							İ					1				1							3-DF	
3 2-D MEASUREMENTS	MEAS2D											1					1									1		1	1		4-DF	1
4 M-MODE and DOPPLER MEASUREMENTS	MMDOP											1				<u> </u>	1	1					1			1		1	1		5-DF	-
5 Tomtec	TOMTEC											1				1		1										1	1		6-DF	-
6 Signature Completion	SIGN															-	+	-					1		-		1			-		1

s	DEIT: System Screening (SYSSCR) [frSYSSCR1]								
s	m Screening (frSYSSCR1)								
1	* Check box to screen subject into Inform system. [Check to screen subject]	(SCRSUB) /№ 1) □Screen Subject							
2	System generated initials (hidden) [System generated initials]	[SUBJINIT] A3							
	Key: [*] = Item is required								

UIDEIT: System Enrollment (SYSENR) [frENRSYS2]							
System Enrollment [frENRSYS2]							
1.* Check the box to enroll the subject into the InForm system. [Check to enroll subject]	[ENRSUB.] /№ 1/ □Enroll Subject						
Key: [*] = Item is required							

sdguideit: RAND (RAND) [frsirerand]	
Randomization [stRAND1]	
1. Patient Number (read-only) [Patient Number]	[RSUBJD] A200
Randomization Information [stRAND2]	
2.* Does subject qualify for study? (Does subject qualify for study?)	[Reconduct]           [Reconduct]           [Reconduct]
3. Arm (read-only) [Arm]	[ARM] A200
Site Randomization date/time (read-ody)     [Site Randomization date/time)	SHIEDMI           Reg U / Reg U / Reg U (2011-2020)           Reg U / Leg U / Leg U (2011-2020)
<ol> <li>Check this box if a randomization error message appears in Arm question above and the form needs to be resubmitted to populate Arm with randomization information [Re-submit]</li> </ol>	[RESUBMIT] [/k:1] [][Resubmit
6. Cohort (hidden)	[COHORT] N10
STRATA [stRAND3]	
7. STRATA 1 (hidden) [STRATA 1]	[STRATA1] A200
8. STRATA 2 (hidden) [STRATA 2]	[STRATA2] A200
9. STRATA 3 (hidden) (STRATA 3)	[STRATA3] A200
10. [STRATA 4 [hidden] [STRATA 4]	ISTRATAA] A200
Key: [*] = Item is required [ *] = Source verification required	

GUIDEIT: Clinical Operations review ( te: Entered by CRA only. Hidden to sites.	CLINOPS) [frCLINOPS]					
te: Entered by CRA only. Hidden to sites. gibility criteria [stCLINOPS1]						
Per eCRF eligibility review, was subject found to be eligib [was subject found to be eligible?]	le?		[INCMET] [N:1] ① Yes [N:0] ⑦ No			
Criteria	Additional comments	Was a waiver granted		granted waiver	Narrative	Narrative continued
igible criteria Entry [rsCLINOPS2]			I			
Criteria (Criteria) Additional comments about eligibility criteria (Additional comments)			(N 3) Obtain recent document bicker or reveals) (N 4) Oht Pro SMP > 2000 P; (N 3) Oht Pro SMP > 2000 P; (N 3) Obtained (N 2) Obtained (N 3) Obtained (N 2) Obtained (N 3) Obtained (N 2) Obtained (N 2) (N 4) Obtained (N 2) Obtained (N 2) Obtained (N 2) (N 4) Obtained (N 2) Obtained (N 2) (N 4) Obtained (N 4) (N 4) Obt	ymL or BNP > 400 pg/ml any time during the 30 days primed consent ormed consent and (based on clinical judgment) or cardiac revascularizz ation therapy (CRT) within prior 3 months or current plan peertrophic obstructive cardiomyopathy, percardits, or n inter disease splanation or ventricular assist device within 12 month rapy eard disease is with recard replacement therapy liness with expected survival less than 12 months mat or claning to become personan.	of randomization. This assessment must occur at leas for to randomization ation procedure within 30 days to implant CRT device estrictive cardiomyopathy	verload 12 weeks after any intervention likely to improve EF (CRT, Be
Was a waiver granted? [Was a waiver granted]			[WAIVER] [№:1] ①[WAIVRDT] Ves Date  Req ♥ /  Req ♥ /  Req ♥ (201: [№:0] ⑦NO	2-2025)		
I Who granted waiver? [Who granted waiver]			[WHOGRTWV] A200			
Reason for waiver narrative [Narrative]			[ELIGNRT] A200			
Reason for waiver narrative continued [Narrative continued]			[ELIGNRT1] A200			
			ICF review			
ormed consent Entry [rsCLINOPS3]						
ICF review [ICF review]			IC FREVADJ /# 12 ○CICFREVDT) Ves ICF review complete date ICF review complete date ICF version ICF version /# 200 /#	2-2025)		
Review date	Data surveillance type	Main Topic	Visit reviewed	Forms reviewed	Findings	Resolution Date
ta Surveillance Review Entry [rsCLINOPS4]				l		I
I Verification review done[/hidden] [Verification review done]			[SDV00K] /× 1) USDVRVV) Ves Weilion review done after w (N-1) 2 Baseline (N-2) 2 weck (N-2) 3 month (N-4) 3 month (N-4) 3 month (N-4) 9 month (N-7) 12 month (N-7) 12 month (N-7) 21 month (N-7) 24 month (N-10) 24 month (N-12) 24	Nich visit?		
2 Date of Review [Review date]			[CORVWDT]  Req ♥ /  Req ♥ (2012-2025)			
What type of Data Surveillance was conducted? [Data surveillance type]			[COSURVLC] [N: 1] Data Review [N: 2] Source Document Verification			
Main Topic [Main Topic]						
9 Was visit(s) reviewed? [Visit reviewed]			[COVSTRV] /#:1) ①[EyPSTRV] Ves (COSKN] /#:1) □[Baseline (CO2WC] /#:1) □] Weeks [CO2WC]			

			[N:1] 2 Weeks Follow-up		
			[CO6WK] [/N:1]6 Weeks		
			[CO6WKFU]		
			[N:1]6 Weeks Follow-up [CO3M0] [N:1]3 Months		
			[N:1] 3 Months [CO3MOFU]		
			[CO3MOFU] (N:7) [] 3 Months Follow-up		
			[CO6MO] [/::1] 6 Months		
			[CO6MOFU] [N:1]6 Months Follow-up		
			[CO9MO] [N:1] 9 Months		
			[CO9MOFU] [N:1] 9 Months Follow-up		
			[CO12MO] [N:1] 12 Months		
			[C012MOFU] [N:1] 12 Months Follow-up		
			[0:1] [2 wonth's robov-up [Co15M0] [N:1] [15 Months		
			[CO15MOEU]		
			[/k:1] [] 15 Months Follow-up [CO18M0]		
			[C018MO] (N:7) [] 18 Months (C018MOEU)		
			[C018MOFU] [N:1] 18 Months Follow-up		
			[C021M0] [/v:7] 21 Months		
			[CO21MOFU] (N:1) 21 Months Follow-up		
			[CO24MO] [N:1] 24 Months		
			[CO24MOFU] [N:1] 24 Months Follow-up		
			 (N:0) ONO		
I.6 Was form(s) reviewed? [Forms reviewed]			[COFRMRW] [N: 1] O[C9FRMRW] Yes [CODEM]		
			Yes [CODEM] (N: 1) Demographics		
			[N:1] □ berrographics [COMEDHX] [N:1] □ Medical History		
			[COBASE]		
			(N: 1) Baseline [COEXAM]		
			[COEXAM] (N: 7] Examination [COMED]		
			[COMED] [N:7] [Medications [COMTERO]		
			[CONTPRO] [N:1] [INT-proBNP		
			[COLABS] (N: 1) Labs		
			[COBIOBNK] [N:1] Biobank		
			[COCSNT] [N:1] Consenting to Biorepository		
			[COADJUST] [N:1] Adjustment		
			[COCONTCT] [N:1] Contact		
			[COASSMT] [N:1] ☐ Assessment		
			[N:1] Assessment [OcAs] [N:1] Cross Active Study Trigger Form		
			[N:1] Cross Active Study Trigger Form [COAE] [N:1] AEs/SAEs		
			[N:1] AES/SAES		
			[COEXTRD] [N:1] [Extended Care [CODDV1]		
			[CODOV] [N:1] Date of Event		
			[COHOSP] [N: 7] Hospitalization		
			[COACS] [N:1] Acute Coronary Syndrome		
			[COHF] (N:1) Heart Failure		
			[COEOS] (N:1) End of Study		
			[CODEAD] [N:1] Death		
			 [N: 0] (NO		
I.7 Findings/Trends Discovered [Findings]			[COFINDND] [N: 7] [COFINDNS]		
			(N: 1) ©[COFINDNS] Yes Findings/Trends Description		
			( new)		
			[N:0] No		
I.8 Resolution Date (Resolution Date)			 [COREST] [Req V / Req V / Req V (2012-2025)		
[Resolution Date] Main Category	Sub Category	IRB Reportable	 Req V / Req (2012-2025) IRB Acknowledgement Date	Resolution	Resolution Date
5.			<u> </u>		
Deviation Tracking Entry [rsCLINOPS5]			 [MAINCAT]		
[Main Category]			[N:1]         [Inclusion/Exclusion           [N:2]         [Informed Consent Form           [N:3]         [Laboratory Assessments		
			(N: 3) Laboratory Assessments (N: 4) Study Procedures		
			[ <i>N</i> : 4] Study Procedures [ <i>N</i> : 5] ↓Vist Schedule [ <i>N</i> : 6] ↓ Randomization Procedures		
			(N: 7) CAEs/SAEs		
			[N: 98] [MANCATOT]		
			Other		
			(In: 7) AES/SAES (In: 90) Ottomore Ott	1	

		A200
5.2	Sub Category (Sub Category)	[SUBCAT]           A200
5.3	189 Reportable [IR8 Reportable]	[REPORTA] [#±7] ©Yes [#±0] ©No
5.4	IRB Acknowledgement Date (IRB Acknowledgement Date)	[I RBACKDT] Req v / Req v / Req v (2012-2025)
5.5	Resolution [Resolution]	[PESOLTN] A200
5.6	Resolution Date [Resolution Date]	[RES_TNDT]           [Req V]         / Req V         (2012-2025)
к	y: [*] = Item is required (v) = Source verification required	

Codelist RefName	Codelist Data Type	Label	Code	Codelist Item RefName	Data Variable RefName	
CTCOMNTPC	Integer	CEC Follow-Up	1	ciCEC_FU	COMNTPC	
		CRF Question/Issues	2	ciCRF_Question		
		Clinical Question		ciClin_Question	1	
		Core Lab	4	ciCore_lab		
		Data Quality	5	ciData_Quality	1	
		GCP/ICH	6	ci_GCP_ICH		
		ICF-Major	7	ciICF_Major		
		Inc/Exc Criteria	8	ciCriteria		
		InForm eCRF Access	8 ciCriteria 9 ciInformAccess	ciInformAccess		
		Other Study/Site Issues	10	ciOthIssues		
		PI Oversight	11	ciPIOversight		
		Patient Follow-Up	12	ciPatFU		
		Protocol Deviation	9         ciInformAccess           10         ciOthIssues           11         ciPlOversight	ciProtocal_Dev		
		Query Resolution	14	ciQueryRes	]	
		Safety Follow-up	15	ciSafetyFU		
		Site Performance	16	ciSitePerf		
		Source Documentation Verification	ntation Verification 17 ciSourceDocVerif	ciSourceDocVerif	]	
		Sub-Study	18	ciSub_study	1	
		Training	19	ciTraining		
		eCRF Completion	20	cieCRF_Comp	1	

sdGUIDEIT: Clinica	I Operations review of withdrawn (CLINOPSWD) [frCLINOPSWD]						
Entered by CRA only. Hidde	n to sites.						
Withdrawal status [stCL	NOPSWD1]						
<ol> <li>Did the subject withdran [Subject status]</li> </ol>	17	$ \begin{array}{c} [ \text{COVTHOR} ] \\ [ \hbar : T ] & \hline \\ \text{Ves} \\ \text{Date of Withdrawal} \\ \hline \\ \text{Res} [ \omega & \uparrow   \text{Res} [ \omega & \downarrow   \text{Res} [ \omega & \sqcup   \text{Res} [ \omega & \sqcup   \text{Res} [ \omega & \sqcup   \text{Res} [ \omega & $					
2 Subject Agreed to Limit [Limited Participation]	d Participation?	[COLTDET] /* 7) ○[SELTDET] /*S (CONTONE) /* 7) ○[SELTDET] /* 7) ○[SELTDET] Other 5 Other 5 Ot					
3. Will allow for contact to [Contact at EOS]	determine allve at end of study?	(COCOSFU) /// 1/ 1/ Yres // an @No					
	Date Updated	Current Update	IRB date				
4.							
Withdrawal Entry [rsCLI							
4.1 Date of Current Update [Date Updated]	1	[COWTHUDT] Req ♥ / Req ♥ / Req ♥ (2012-2025)					
4.2 Current Update [Current Update]		[COWTHCDT]  Req ♥ /  Req ♥ /  Req ♥ (2012-2025)					
4.3 IRB Acknowledgement [IRB date]	Date	[COIRBWDT]  Req V / Req V / Req (2012-2025)					

sdGUIDEIT: CEC manual triggers (CECMT) - Repeating Form [frCECMT]		
# Date of the unreported event	Type of event	Trigger number
1		
CEC manual triggers [stCECMT1]		
1. Date of the unreported event [Date of the unreported event]	[MNEVNTDT]  Req   /  Req   /  Req   (2012-2025)	
2. Type of event [Type of event]	[EWNTYPE] [N:1] ⊙Hospitalization [N:2] ⊙ Death	
3. Trigger number [Trigger number]	[MANTRIG]   A100	

sdGUIDEIT: CAS Trigger form (CASTRIG) [frCASTRIG]							
CAS Trigger form [frCASTRIG]							
1.* Did subject have any Serious Adverse Events of Safety Events of Interest? (AE?)	[CASAE] [№ 1] ◎ YMS [№ 0] ◎ NNO						
2.* Did the subject have any actended care admissions? (Extended care admission?)	[CASCEF] [0:1] © Y <sup>A</sup> S [N:0] © No						
Key: [*] = Item is required [ *] = Source verification required							

sdGUIDEIT: Adverse events (AE) - Repeating Form [frAE]

#	Adverse event of interest Onset Date and Time End Date Final Outcome Severity Serious? Primary cause of the	event Are there any laboratory/diagnostic tests	? Lab/diagnostic test	Was the patie	nt taking any relevant concomitant medication	Concomitant medications	SAE NARRATIVES	Form accurately displays the results of the examination	Evaluation Date and Time
Adv	erse event [stAE1]								I
	Adverse event of interest:			[AESTAT]					
~	[Adverse event of interest]			[N:1] OSyr	nptomatic hypotension nptomatic bradycardia				
				(N:2) OSyn	perkalemia				
				[N:4] OWO	rsening renal function				
				[N:98] [AE Oth	TERM] er Adverse event cify Adverse event:				
				Spe	cify Adverse event:				
				A1	00				
2.*	Onset Date and Time (Onset Date and Time)			[AESTDTM]					
2.* •	[Onset Date and Time]				Req/Unk 🖌 / Req 🖌 (2012-2025)				
					Req/Unk v 24-hour clock				
3.* •	End Date [End Date]			[AEONGO] [N:1] OCont	inuing				
1				[N:2] [AEE	NDT]				
				req	onk v / Red/onk v / Red v (2012-2025)				
4.	Final Outcome (Final Outcome)			[AEOUT] [N:1] ORes	olved				
				[N:2] ORes	olved with sequelae				
				[N:3] On [N:4] ODe	going				
				[N:4] ODe	nown				
5.* •	Severity [Severity]			[AESEV]					
~	[Severity]			[N:1] OMild [N:2] OMod	proto				
				[N:2] Owod [N:3] OSeve	re				
6.* •	Was this adverse event serious?			[AESER]					
-	[Serious7]			[N:1] [AES	LIFE]				
				Seri	ous criteria:				
				[SAE	Life threatening  PRO]				
				[N: 1	Required prolongation of existing hospitalization				
				[AES /N·	DI SAB]				
				[AES	Persistent or significant disability				
				[N: ]	<ul> <li>Congenital anomaly/birth defect</li> <li>MIE]</li> </ul>				
				[N·:	Important medical event				
-				[N:0] (NO					
7.* •	Please specify a primary cause of the event: [Primary cause of the event]			[SAEDTLS] [N:1] [ST	DYPRC]				
				Stu	dy procedure cify study procedure				
				A2					
					nary disease under study				
				(N:2) OPTI	ecilli				
				Int	ECILL] ercurrent illness wify illness				
				A2					
				[N:4] [PF	OBNPAE] proBNP machine				
				[N.	<ol> <li>Due to malfunction</li> </ol>				
				[N.	2) ODue to failure				
				(M-5) CCC	3) Due to user error				
				Cor	comitant medication (if checked, please answer question cify concomitant medication	below)			
				A2					
				[Mi Wh	EDACTN] at was the action taken with the concomitant medication?				
				[N.	<ol> <li>Dose not changed</li> </ol>				
				[N. /N	2) ODse reduced 3) ODrug discontinued				
				[N.	3) Drug discontinued 4) [EVNTDIM]				
					If interrupted If interrupted or discontinued, did the event diminis	h?			
					[N: 1] OYes				
					[N: 0] ONO [MEDRESTR]				
					Was the drug restarted?				
					[N: 1] OYes - event reappeared [N: 2] OYes - event did NOT reappear				
				(1) and (1)	(N: 0) 🔿 NO				
				(N:98) [SA Oth Oth	er				
				OtP A2					
				<sup>^</sup>					
8.*	Are there any laboratory/diagnostic tests? (If yes, complete add entry laboratory/diagnostic tests)			[SAELAB]					
-	[Are there any laboratory/diagnostic tests?]			[N:1] OYes [N:0] ONO					
	Name of lab/diagnostic test	Date of test	Result	Unit	Lower limit	of normal		Upper limit of normal	
9.									
Lab	/diagnostic test Entry [rsAE2]								
Lab				[LABNAME] A200					
Lab	/diagnostic test Entry (rsAE2) Name of lab/diagnostic test (one per entry) (Name of lab/diagnostic test)			[LABNAME] A200					
Lab				A200					
Lab 9.1 ✔	Name of lab/diagnostic test (one per entry) [Name of lab/diagnostic test]			A200					
Lab 9.1 ✔				A200	♥ /  Req ♥ (2012-2025)				
9.1 • 9.2 •	Name of lab/diagnostic test (one per entry) [Name of lab/diagnostic test] Date/time of test [Date of test]			A200 [LABTSTDT] Req V / Req Req/Unk V :	♥ /  Req  ♥ (2012-2025) ReqUitk  ♥   24-hour clock				
9.1 • 9.2 •	Name of lab/diagnostic test (one per entry) [Name of lab/diagnostic test] Date/time of test [Date of test]			A200	Req/Unk 24-hour clock				
9.1 • 9.2 •	Name of lab/diagnostic test (one per entry) [Name of lab/diagnostic test]			A200 [LABTSTDT] Req V / Req Req/Unk V :	Req/Unk 24-hour clock				

9.4 Unit 9.5 Lower limit of 1 Lower limit of 9.6 Upper limit of 1 Upper limit of 2 Concomitant me	f normal normal f normal dication [stAE3] ent taking any relevant concomitant medication from 30 days prior to onset of the event (if yes, complete	idd entry concomitant medications)		[LABINFM]           Was the result normal?           (N: 7)         [Abnormal           (N: 7)         [Abn			
✔ [Was the par	ient taking any relevant concomitant medication]			[N:1] OYes [N:0] ONo			
	Concomitant medication	Total Daily Dose	Units	Route	Start date	Stop date	Indication for use
11.							
11.1 Concomitan Concomitar				[AEDRUG] A200			
11.2 Total Daily E Total Daily	lose Dose]			[TDD] XXXXXXXXX.			
11.3 Units Units				[DRUGUNIT] A50			
11.4 Route ✓ [Route]				IDRUGRTE) A50			
11.5 Start date ✓ [Start date]				[DRGSTRDT] Req/Unk / Req/Unk / Req	(1995-2025)		
11.6 Stop date ✓ [Stop date]				[DRUGSTP] [N:1] [DRGSTPDT] [Req/Unk ] / Req/Unk [ [N:2] [Ongoing	/ Req 💟 (2012-2025)		
11.7 Indication fo Indication f	r use [			A200			
			SAE NARR	ATIVES			
12.	5 F-4 5 4FC3						
12.1 SAE NARRATIVE	IVES			[SAENAR]			
✓ [SAE NARRA	TIVES)			A200			
	ator SAE Electronic Verification [stAE6]						
13. I verify that [Form accur:	this SAE report form accurately displays the results of the examination, tests, evaluations and treatments n tely displays the results of the examination]	oted within.		[MDRVW] [N:1] OYes [N:0] ONo			
14. Evaluation D [Evaluation I	ate and Time (Electronic Verification non-enterable system generated) late and Time]			Req         I         Req         I         Req         I         Req         I         Req         I <th< th=""><th>025)</th><th></th><th></th></th<>	025)		
Key: [*] = Item is	required [ 🗸 ] = Source verification required						

ended care [frEXTCARE] Admission date [Admission date]	EXTADIOT           Beq ▼ / Req ▼ / Req ▼ (2012-2025)	
Admission date [Admission date]		
[Admission date]	[EXTADMDT]	
	(2012-2025)	
Type of extended stay facility (Type of extended stay facility)	(FVPFAC)           (#:1) (7 Sellied nursing           (#:2) (7 Sellied nursing           (#:2) (7 Sellied nursing           (#:2) (8 Sellied nursing           (#:2) (9 Sellied nursing<	
Was the subject discharged? [Was the subject discharged?]	Iterrity     Iter	te a HOSP form piete an additional EXTCARE form

# Keys (navigation)/Uniqueness: Extended care Item Unique Order # frEXTCARE (Repeating form) Item Item

frEXTCARE (Repeating form)				
EXTADMDT	Individual	1		
EXTRONOT	marvidda			

S	sdGUIDEIT: Date of evaluation (DOE) [frDOE]		
Date of evaluation [frDOE]			
1.	Date of evaluation	[EVALUDT]  Req 💟 /  Req 💟 /  Req 💟 (2012-2025)	
2.	Type of visit [Type of visit]	(vistrop)           (n: r) ○Telephone visit           (n: 2) ○ In person visit	
3.	Delete visit - site created the visit by accident [hidden] [Delete visit]	[DELETVIS] /№ 17 □ Yes	
	Key: (1) = Item is required [*] = Source verification required		

Key: [\*] = Item is required [ ] = Source





13.*	Mitral valve repair/replacement? (Mitral valve repair/replacement?)	[MITRLVLV] [N:1] OYe	
	(Murai Vaive repair/replacement /)	[N:0] ONG	S
14.*	Ablation? [Ablation?]	[/ [/	ason 11Ahb/Tutter/SVT 22
15.*	[PVD interventions?]	[PVD] [N:1] ①Ye [N:0] ②No	s
16.*	Mechanical ventiliation (Mechanical ventiliation)	[MECHVENT [N:1] OYe [N:0] ONO	1
		[ULTFILT]	
17.	(Ultrafilration)	[N:1] OYe [N:0] ON	s ,
18.*	Dialyskis (acute) [Dialyskis (acute)]	[DIALS] [N:1] OYe [N:0] ONG	5
19.*	IV Inotropes (IV Inotropes)	[INOTRP] [N:1] OYe [N:0] ONe	s 1
20.	(CardioMEMS HF System)	[CMEMS] [N:1] OYe [N:0] ONO	s
Faci	i lity details [stHOSP4]		
		[HSPNAMED	
	[Hospital name]	[N:2] O	nknown
22.	Hospital location	[HSPLOCA]	
22.	[Hospital location]	[N:1] OL	INF.0CAS) IV, State 2000
23."	Was the subject discharged? [Subject discharged?]	[SUBJDIS]	
		(N:1) (N:1) Ye Di (H Di (/ (/ (/ (/ (/) (/)	s of discharge i of discharge i of discharge SpSocied 11 Of Occurs care, complete an additional HOSP form 12 Of Occurs care, complete EXTOARE form 13 Of Occurs care, complete EXTOARE form 14 Of Wome 14 Of Wome
24.	Trigger number	[HSPTRIG]	
	Trager rumber)	A100	
Ke	y: [*] = Item is required [*] = Source verification required		

sdGUIDEIT: Acute coronary syndrome (ACS) [frACS]	
ACS DETAILS [stACS1]	
1.* Date and time of onset of ischemic symptoms that caused the subject to seek medical attention (day and time may be estimated) [Date and time of onset of ischemic symptoms]	Intestitution         Integration
2 <sup>*</sup> Please indicate characteristics of the ischemic symptoms [Please indicate characteristics of the ischemic symptoms]	DMI Score         (#:17) CMC-SEWM         (#:17) CMC-SEWM         Select all that apply         (#:17) CMC-SEWM
a." Type of event [Type of event]	put revery       /rt i) Opportaneous Myocardial Infarction       /rt i) Opportaneous Myocardial Infarction       (rt i) Opportaneous Myocardial Infarction       (rt i) Opportaneous Myocardial Infarction       (rt i) Opportaneous Myocardial Infarction
4. <sup>*</sup> Longest duration of lschemic symptoms [Longest duration of lschemic symptoms]	LONCOUR) [No 0] Ø None (N 1) Ø = 1 0 minutes [N 2] Ø = 1 0 minutes [N 2] Ø = 2 0 minutes [N 99] Ø Uhknown
5. <sup>*</sup> Dd the participant have a cath lab visit during this event? [Did the participant have a cath lab visit during this event?]	Ducativisj (# τ] Ο/Yes (# α) ΟΝο
6." Were ECGs performed for ischemic episode or in follow up?) (I yes, submit the ECG.) (Were ECGs performed for ischemic episode or in follow up?)	[Ecosser]           /k:7         CECosser)           Yes         Were there new ischemic changes?           /k:7         [Xris]           [k:7]         [Xris]
7.* Was there hemodynamic instability related to this event? [Was there hemodynamic instability related to this event?]	[EVHEMOIN]           [N:1] O'Yes           [N:0] O'No           [N:9] OUrknown
B.* Was there heart failure complicating this event? [Was there heart failure complicating this event?]	(MHF)           (N:1)         (Vics)           (N:9)         (Vinknown)
9." Imaging evidence of new loss of viable myocardium? (Imaging evidence of new loss of viable myocardium?)	NetWOSSI           Nr 1         ○[M#FETYP]           Yes         Type of imaging performed           Nr 1         ○[EGH0           Nr 1         ○EGH0           Nr 2         ○MR           Nr 3         ○MR           Nr 3         ○MR           Nr 3         ○MR
CRA confirmation of missing ACS data (DCRI use only) [stACS2]	
10.     This record was intentionally left blank. Please delete.       [This record was intentionally left blank.]       CEC patient profile print date [stAcS3]	(M UNDCON) (№ 1) ©Confirm
	[CECACS]
11. Date/Time Patient Profile printed [Date/Time Patient Profile printed]	(IceCarS)         Reg v / Reg
Key: [*] = Item is required	

dGUIDEIT: Hospitalization for heart failure (HF) [frHF] EART FAILURE (SHF1)	
Indicate clinical symptoms of heart failure (Select all that apply) [Indicate clinical symptoms of heart failure]	IP # 70 CPUFORSP         (N: 7) CPUFORSP         (N: 7) CPUFORSP         (H=000000000000000000000000000000000000
	[n, i] interval $[n, i]$ interval $[n, i]$
<ul> <li>Indicate physical signs or objective signs of heart failure (Select all that appy) [Signs of heart failure]</li> </ul>	IP is a constraint of the set of th
Initiation of, or an increase in, treatment directed of heart failure (Select all that apply) (Initiation of, or an increase in, treatment directed of heart failure)	IPETROTING (N: 1)       (V: 1)       [Initiation of IV divertic, inotrope, or vasciliator therapy or significant augmentation of therapy (IV: 1)         IPETROTING (N: 1)       [Initiation of IV divertic, inotrope, or vasciliator therapy or significant augmentation of therapy (IV: 1)         IPETROTING (N: 1)       [Initiation of mechanical or surgical intervention (N: 1)         Other, specify       [Initiation of mechanical or surgical intervention (N: 1)         IPETROTING (N: 1)       [Initiation of mechanical or surgical intervention (N: 1)         IPETROTING (N: 1)       [Initiation of mechanical or surgical intervention (N: 1)         IPETROTING (N: 1)       [Initiation of mechanical or surgical intervention (N: 1)
RA confirmation of missing HF data (DCRI use only) [stHF2]	· ·
This record was intentionally left blank. Please delete.	(HFNDCON) <i>(№ 1)</i> ©Confirm
(Please delete.)	(h:1) @Confirm
EC patient profile print date [stHF3]	
Date/Time Patient Profile printed [Time profile printed]	[Rec]         //         [R

sdGUIDEIT: Subject Demographics (DEM) [frDEM]				
Subject Demographics [frDEM]				
1. Update Workflow (hidden) (Update Workflow)	[UPDTWKFL] [N:1] []Yes			
2. Update subject number (Update subject number)	[SUBJID] A50			
3.* Date of birth (Date of birth)	ID00DT1         Req V         / Req V         (1900-2008)			
4.* Gender [Gender]	[GENDER] [/k:1] @ Male [/k:2] @ Female			
5.* [Etholaty] [Etholaty]	(EFHNIC)         [Mitpanic or Latino           [N:2]         [Molt Hepanic or Latino           [N:2]         [Molt Hepanic or Latino           [N:9]         [Molt New York			
6.* Race	Field         [Internet           [Internet         [Internet           [Inter         [Inter			
7." Height [Height]	[HTOONE] [W1] ①[HÉGHT] [V07] ②[NETONE] [W27] ②[NETONE] [W1] ①[NETONE] [W1] ③[NETONE] [W1] ④[NETONE] [W1]			
8. Weight /hidden/ [Weight]	(wetron)           /k:1)         Ottoget           xcccccccc.         Ottoget           /k:2)         Not Done			
Informed Consent [stDEM2]				
9.* Date and time of consent (Date and time of consent)	COUNTDY         Req V         <			
10.**     Outstying NT-proBNP or BNP value:       •     (Qualifying NT-proBNP or BNP value:)	(INDXMRKC]         (N:1) ○[cpAP]         (NXXMP07]         (NXXMP7]         (NXXMP)         (NXXMX)         (NXXXXXX)			
Key: [*] = Item is required [ • ] = Source verification required [b] = Base Unit				

	UIDEIT: Medical History (MEDHX) [frMEDHX]	
	al History [f/MEDHX]	batuofi
•	What is the primary etiology of the heart failure?	(IPE IT 0) Eschemic (IV 27) [OHISTE 0] (IV 27) [OHISTE 0] (IV 27) [OHISTE 1] (Idepathic (IV 27) [OHISTE 1] (Idepathic (IV 27) [OHISTE 1] (IV
2.*	Duration of heart failure)	(H-DUR)  N: ] (H-DUR)  N: ] (V: 91) (Vincour)
3.*	Has the subject had any hospitalizations for heart failure] (Fas the subject had any hospitalizations for heart failure)	IN T/ CILSTINGOT] Ves, Date of the last hospitalization for heart failure [seq/task ] / [seq/task
Indic	ate if the subject has had a history of the following [stMEDHX2]	
4. <sup>×</sup>	Coronary artery disease (CAD) [Coronary artery disease (CAD)]	[CAD]  N:1] Q <sup>™</sup> S  N:2] Q <sup>™</sup> S
5. <sup>*</sup> I	Prior revascularization (If yes, check all that apply) [Prior revascularization]	[CABOS] [N:1] [O[cpcABOS] Ves [Pec] [PC] [PcaD] [N:1] [] ABG [N:1] [] ABG
6.* •	Valve surgery] [Valve surgery]	INIT DICENTISES LOOP VISION NOT DICENTISES LOOP VISION NOT DICENTISES NOT
	Prior Implantable cardioverter defibrilitator (ICD) Placemaker Implantation (Prior Implantable cardioverter defibrilitator (ICD))	Incorport           [N:1] Uron           [N:1] Ves           [N:1] Oron
8.* I	Myocardial Infarction (MI) (Myocardial infarction (MI))	[PM] /*7.7 ○[MIF7] Yes, Year of most recent /*7 ○ [Mie30] /*7
~	Prior left heart catheterization (Prior left heart catheterization)	[LHC] /#x1 / ○[LHSTEND] Ves Did any vessel have >70% stenosis? /#x1 / ○[Ves /#x0 / ○[No /#x0 / ○[No
10.* •	Artist fibrillation/flutter (Atrist fibrillation)	(M1)         0           (M2)         0
*		(VF18)           (N1)         (Vris           (N0)         (No           (PAVD)         (PAVD)
	Peripheral arterial vascular disease Peripheral arterial vascular disease Strake	(N:1) QYes (N:0) QNo EXEMPT
	Stroke Stroke	
	Hypertension [Hypertension] Diabetes mellitus	[N:1] QYes [N:0] QNo [DIABETES]
<b>~</b>	Chronic respiratory disease (e.g. COPD) (Chronic respiratory disease)	[ <i>N</i> :1] QYes [ <i>N</i> :0] QNo [Core]
×	[Chronic respiratory disease] Chronic liver disease	[N:1] QYes [N:0] QNo [UvEn]
17.*	Chronic II: Ver disease)	[N:1] QYes

19.*	Cigarette smoking	[SMOKEHX]
~	[Cigarette smoking]	[N:1] ①Yes
		(N:0) (NO
20 *	Acchol abuse (Acchol abuse)	[ALCOHOL]
	(Alcohol abuse)	[N:1] OYes
		[N:0] ONO
21.*	Depression treated with medications (Depression)	[DPRSNMED]
~	(Depression)	[N:1] QYes
		(N:0) (NO
22 *	Drug abuse	[DRUG] /N:1) <sup>(D</sup> Yes
	Drug abuse [Drug abuse]	(N:1) OYes
		[N:0] QNO
23.*	Hyperlipidemia (Hyperlipidemia)	[FAT] //k:1/ ①YES
	(Hyperlipidemia)	(N:1) OYes
		[N:0] [No
24.*	Skep apna [Skep apna]	[APNEA]
~	(Sleep apnea)	(N:1) OYes
		(N:0) (NO
25.*	Renal disease [Renal disease]	[KIDNEY]
~	[Renal disease]	[N:1] OYes
		( <i>N</i> :0) (No
26.	CardioMEMS HF System	[CMEMSMHX]
	[CardioMEMS HF System]	[N:1] QYes
		(N:0) No
Ke	* * = Item is required [v] = Source welfcation required	

Key: [\*] = Item is required [ \* ] = Source verification required

GUIDEIT: Baseline Assessments (BASE) [frBASE]	
tex hospitalization discharge [stBASE1]	
Date of qualifying event [Date of discharge ]	
Type of qualifying event [Type of qualifying event]	IOLFYNTYP)         [N:1]       Outpatient         [N:2]       Outpatient         [N:3]       Outpatient         [N:4]       Outpatient      [
sessments [stBASE2]	(A-31) [UKLOM]
Date of baseline assessment (Date of baseline assessment)	(BASASCDT)   Req ♥ /   Req ♥ /   Req ♥ /   Req ♥ (2012-2025)
Were local labs performed? (If yes, please complete LABS form) [Were local labs performed?]	[5T0YLAB1] [N:1] Ores [N:2] O Subject refused
Were protocol required biological samples collected? (If yes, please complete BIOBANK form)	teiccori         [k: 1] Q <sup>+</sup> tes           [k: 2] Q <sup>+</sup> tes         [k: 2] Q <sup>+</sup> subject refused
Was 6-minute walk performed?	[N:1]       [WatKKN]         Ves.       Distance walked (meters)         I/N:1]       [WatKN]         I/N:1]
Were baseline OOL forms administered? [Were baseline GOL forms administered?]	[00LF0RMS] /№ 1] ©Ytes /№ 0] ©No
Did the subject have an echo performed? (perficuble for 50% sub-Sub-Sub performed?) (Did the subject have an echo performed?)	Image: Concentration of the state of t
Was therapy adjusted? (If yes, please complete ADJUST form) (Was therapy adjusted?)	Image: Personal intervence       Image: Personal intervence         Image: Personal intervence       Image: Personal intervence         Image: Personal intervence       Image: Personal intervence         Image: Personal intervence       Image: Personal intervence         Image: Personal intervence       Image: Personal intervence         Image: Personal intervence       Image: Personal intervence         Image: Personal intervence       Image: Personal intervence         Image: Personal intervence       Image: Personal intervence         Image: Personal intervence       Image: Personal intervence         Image: Personal intervence       Image: Personal intervence         Image: Personal intervence       Image: Personal intervence         Image: Personal intervence       Image: Personal intervence         Image: Personal intervence       Image: Personal intervence         Image: Personal intervence       Image: Personal intervence         Image: Personal intervence       Image: Personal intervence         Image: Personal intervence       Image: Personal intervence         Image: Personal intervence       Image: Personal intervence         Image: Personal intervence       Image: Personal intervence         Image: Personal intervence       Image: Personal intervence         Image: Persona intervence       Image: Persona in

sdGUIDEIT: Recent Ejection Fraction (EF) [frEF]		
Recent Ejection Fraction [frEF]		
1.* Most recent ejection fraction date [ejection fraction date]	Image: Image:	
2.* Value of most recent LVEF (Enter description only if EF value unavailable) Vilue of most recent LVEF]	IVEFy         [V:FVAL]           [P: 1] ①         [IVEFVAL]           [P: 2] ②         [Veromati           [P: 2] ②         [Veromati           [P: 3] ②         [Vidid dystunction           [P: 4] ③         [Veromatic dystunction           [P: 4] ③         [Veromatic dystunction           [P: 4] ⑤         Severe dystunction	
3.* [Method of assessment of LV function [Method of assessment of LV function]	IMPTHVJ         [N:1]         [Refacinucide ventriculogram           [N:1]         QE factorucide ventriculogram by cardiac catheterization           [N:3]         QE factorucide gram           [N:4]         QMRI           [N:4]         QMRI           [N:4]         Questry	
Key: [*] - Item is required [*] - Source verification required		

IGUIDEIT: Examination (EXAM) [frEXAM] vdate to historical findings [stEXAM1]											
Update to instorical Indings [str.kAw1]            Nev York Hard Association Class         [NVHACD]											
[New York Heart Association Class]	(w)1         01           (w)2         011           (w)3         011           (w)4         01V           (w)47         01V										
Orthopnea (Number of pillows at 10 cm/pillow) (Orthopnea (Number of pillows at 10 cm/pillow))	[ORTHOON]           [Mot] ©0           [Mot] 0           [Mot] 0           [Mot] 0           [Mot] 0           [Mot] 0           [Mot] 0										
ysician Findings [stEXAM2]											
Weight [Weight]	[Weishin]         [Weishin]           [xxxxxxxx]         [Das <sup>[b]</sup> ]           [xxxxxxxx]         [Das <sup>[b]</sup> ]										
Heart Rate (sitting or resting) (beats/min) [Heart Rate]	[HROOKE] (h17) (GHRVAUE) (xxxxxxxxxx) (h17) (GHRVAUE) (xxxxxxxxxx) (h17) (GHRVAUE) (xxxxxxxxxxx) (h17) (GHRVAUE) (xxxxxxxxxxxxx) (xxxxxxxxxxxxxxxxxxx										
Respiratory Rate (sitting or resting) (breaths per min) [Respiratory Rate]	[ISDONE]         [ISVALUE]           XXXXXXXXX         [N+97]           [N+97]         [Not Done										
Blood Pressure (sitting or resting) (mmHg) (Blood Pressure )	[/k-97] ©kict Done [RepOnd: [/k-77] ©[cp8P] [/k-77] [k-2] [/k-77] [k-2] [/k										
Is the patient currently in artial flurillation or artial fluriter? [Is the patient currently in atrial flurillation or atrial flutter?]	(PN:YM)           (PV:T)           (PV:T)           (PV:T)           (PV:T)           (PV:T)										
\$602 (%) [\$p02 (%)]	[IP-0200NE]           (h17)         [ISP02]           L0000000         [IN00000000           (h17)         [IN00000000           (h17)         [IN00000000										
Applier venous pressure (cm) [Jugular venous pressure (cm)]	$ \begin{array}{c} [ VPONNE] \\ [ (N+1) & \bigvee_{Ves} \\ [ (N+1) & \bigcup_{Ves} \\ [ (N+1$										
Rates     [Rates]	[PALESON]         [N:1]         [Charles]           [N:1]         [Charles]         [Charles]         [N:1]           [N:1]         [Charles]         [N:1]         [Charles]           [N:1]         [Charles]         [N:1]         [Charles]           [N:1]         [Charles]         [N:1]         [Charles]           [N:1]         [Charles]         [N:1]         [Charles]           [N:1]         [Charles]         [N:1]         [N:1]           [N:1]         [Charles]         [N:1]         [N:1]           [N:1]         [N:1]         [N:1]         [N:1]           [N:1]         [N:1]         [N:1]         [N:1]           [N:1]         [N:1]         [N:1]         [N:1]           [N:1]         [N:1]         [N:1]										
<ul> <li>S3 auscultation [S3 auscultation]</li> </ul>	[S3AUSC]         [N:1]         Q <sup>1</sup> VEs         [N:0]										
* Hepatomegaly (Hepatomegaly)	[HEPAT]         [Net]         <										
* Acctes [Asctes]	[AsciTES]         [N:1]         QVes         [N:0]										
• Peripheral edema [Peripheral edema]	[IDDRMON]           [N:1] Q           <										
(ay: (*) - Hem is required (*) - Source verification required (b) - Base Unit											



~		(N:1)         [LPOTHRSP]           Other         Other           Other         Other           Total daily dose (mg)         Image: Compare the second s
7.* F	PDE5 Inhibitors)	(k.90)         [Crossin]           (k.91)         [Crossin]           (k.92)         [Crossin]           (k.93)         [Crossin]
8.* (	Medazone ) Metolazone )	[In:Y]
9.* H		(N-1)         O[HCCT2FR0] Ves           (N-1)         O[CHCCT2FR0]           (N-1)         O[CHCCT2FR0]           (N-1)         O[CHCCT2FR0]           (N-2)         O[PN (<1x/week)
10.* /	Ambulatory IV Inotropos Ambulatory IV Inotropos]	[UNING7#] [Ko1] @Yes [Ko2] @No [Ko2] @No
11.* F	Hydralizine]	[krob]           [k
12.* [	Vitrates (long lasting) Nitrates (long lasting)]	[14:7]         Q'instanti           [k1:0]         Q'inst           [k2:0]         Q'inst           [k9:0]         Q'inknown
13.* [	Calclum channel blocker Calclum channel blocker	[key]         Okkomi           [key]         Oyes           [key]         Oyes           [key]         Oyes           [key]         Oyes
14." (	Vniplatelets Anniplatelets)	[AN:1]         O[ANTPASPB]           Ves         [k:1]           [k:1]         [Aspinin (taken daily)]           [k:1]         [Thirtopytidines (e.g., ticdopidine, clopidogrel, prasagrel)           [k:1]         [Thirtopytidines (e.g., ticdopidine, clopidogrel, prasagrel)           [k:1]         [P2r21 nihibitors (e.g., ticdopidine, clopidogrel, prasagrel)           [k:1]         [P2r21 nihibitors (e.g., ticdopidine, clopidogrel, prasagrel)           [k:1]         [MintPasP]           [k:2]         [MintPasP]           [k:2]         [MintPasP]           [k:2]         [MintPasP]           [k:2]         [MintPasP]
15.* (	vaticoaguiants Anticoaguiants]	[ArtTiCAD]         [N:1]       [LATTIWARF]         Yes       [N:1]         [N:1]       [Warfanin         [ANTTKAJ]       [N:1]         [N:1]       [Factor Xia Inhibitor         [ANTTOM]       [N:1]         [N:1]       [Decl. Thrombin Inhibitor         [ANTTOM]       [N:1]         [N:1]       [LegelBy]         Other       [Other]         [Macount       [New Guidencome         [N:2]       [Unknown
16.* E		(bit)         [k:1]         [Ves]           (k:2)         [No         [k:2]         [Unknown
17.* /	tmiodarone	(wind)           (kiii)         (Yes           (kiii)         (Wind)           (kiiii)         (Wind)
18.* ( •	The aniarchythmic	[k+9]         Outstand           [k+1]         O'tes           [k+2]         O'tes           [k+2]         O'tes           [k+2]         O'tes           [k+2]         O'tes           [k+2]         O'tes
	Statin Central	(key) (Junioum [Key] (Jyse (key) (Jyse (key) (No
19.* [		(h.c) QNo
	Lipid lowering agent (other than statin) Lipid lowering agent (other than statin)]	(µ0)         No           (µ0)         Quinkown           (µ1)         Yes           (µ0)         No           (µ0)         No           (µ0)         No

#### Annotated Study Book - sdGUIDEIT

22.*       [Oral anti-diabetic agent]         23.*       Antidepressant (Antidepressant)	IONET (Nr)         QNo           (Nr)         QNo						
24. <sup>*</sup> [Alopurinol]	[N:1]         [Yes           [N:7]         [No           [N:9]         [Unknown						
25.* Bronchodilator (long lasting) [Bronchodilator (long lasting)]	[BEACHORDOR]           Ves           Type of Bronchodilator           I/P of I           Beta 2 agonist           I/P of I           I/P of I           Beta 2 agonist           I/P of I           I/P of I						
26. Valsartan/sacubitril [Valsartan/sacubitril]	[LC2606/N]           [N:1]         QYes           [No]         No           [N'99]         QUnknown						
27. [Vabradine [(Vabradine]	(IVAREDWN)           (N:1)         QYes           (No)         QNo           (N'97)         QUnknown						
Key: (*) = Item is required (*) = Source verification required							

sdGUIDEIT: Local NT-pro-BNP (PROBNP) [frPROBNP]									
NT-proBNP result [sIPROBNP1]									
1.* NT-proBNP testing date (IT-proBNP testing date)	[PBNPDT]         Req         V         /         /         /         /         /         /         /         /         /         /         /         /         /         /         /         /         / <th <="" th=""> <th <="" th=""> <th <="" th=""></th></th></th>	<th <="" th=""> <th <="" th=""></th></th>	<th <="" th=""></th>						
2 * NT-proBNP result (pg/mL)	[Persenses] [N 1]  [N 1]  [N 1]  [N 2] [								
ClinOps discussed results with site     (ClinOps discussed results with site)	(CLNOPAD) [№:1] [№:2] [№:0] [№:0]								
4. Adherence Committee discussed results with site (Adherence Committee discussed results with site)	(ACAD)) [N:1] ○Yes [N:0] ○No								
Key: [*] = Item is required [v] = Source verification required									

Monitoria         Monitoria           Standard         Standard           Standard         Standar		sdGUIDEIT: Local Labs (LABS) [ftLABS]									
Name     Name       Name     Name <t< th=""><th>Cher</th><th colspan="10">Chemistry (sLLABS1)</th></t<>	Cher	Chemistry (sLLABS1)									
Name     Name       Name     Name <t< th=""><th>1.*</th><th>Date of Chemistry Labs [Date of Chemistry Labs]</th><th></th></t<>	1.*	Date of Chemistry Labs [Date of Chemistry Labs]									
Image: Section of Sec	2.*	Solum									
Image: Section of Sec	~	(sourus)	Vilue:								
Markan         Markan           Markan											
Name     Name       Nam     Name <tr< th=""><th></th><th></th><th>[N-27] (mirq/L [N-27] (Nict Dane</th></tr<>			[N-27] (mirq/L [N-27] (Nict Dane								
Image: Section of Sec	3.*	Potassium	[P0TAS5]								
Image: Section of Sec	~	(Potassium)	(N:1) Volue:								
Image: A section of the section of											
Image: Constraint of the constr			[N:1] @mmol/L								
Marine State			[N-2] OmEq/ [N-2] OmEq/								
Image: Section of Section o	4.*	BUN/Urea									
Image: Section of the section of t	~	(an)	(M:1) URWAL Value:								
Internal inte			XXXXXXXX								
Image: Constraint of the constr			[N:1] Ommol/L								
Source In State In Sta			(N-2) Omg/dL (N-21) Omg/dL								
Image: Section of the section of t	5 *	Creatinine									
Image: Section of the section of t	-	(Creatinine)	1/8:17 [CIERATUAL] Value:								
Image: An of the second sec			XXXXXXXX								
In a constrained     A de formationed       In a constrained     A de formationed       In a constrained     In a de formationed       In a de			[CREAUN17] [//:3/Qmg/dL								
Name     Name       Name     Name <t< th=""><th></th><th></th><th></th></t<>											
Image: Section of the section of t		Table Cholesterol	Luent Terrer Control C								
Image: Section of the section of t	•.	Total Cholesterol]									
Image: Section of the section of t											
Internet     Internet       Internet     I											
In and the set of the set o			(N:3) ma/dL								
Image: Section of the sectio			Nerg (Notione )								
Image: Section of the sectio	7.	une ado [Uría add]	LURCU [Re1]								
Image: An and an analysis of the second se			Value:								
Image: A set of the set			[URICUNIT]								
Image: Control of the contro			[N:3] Omg/dL								
Number         Control (Name)         Control (Name)<			[n-4] Qural. (n-2) Qural.								
Date And enclosed and	Herr	atology [stLABS2]									
Newspace       Image: Section of the sect	8.*	Date of Hematology Labs	[HLABD7]								
Image: Contract of the contract	-	[Date on methalology Lats]									
Immediate       Immediate         Immediate	9. V	Hemoglobin									
Image: Constraint of the second of			XXXXXXX								
Image: Control in a in the control in a in the control in a in the control in a in the control in a in the control in a in the control in a in the control in a interval inte											
Instance         Instance         Instance           Instance         In			(M-3) Q-0- (M-3) Q-0-								
Instance       Image: Constraint of the cons			(N:97) ONot Done								
Pateless:       Improvement         Pateless:       Improvement         Visit Order       Improvement	10.*	Hematorit A	· ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~								
Pateless       Image: Pateless (No.2)         Pateless       Image: Pateless (No.2)         Visconse       Image: Pateless (No.2)	-	[Hematocrit]	[N:1] CHEMATVAL] Value:								
Image: North Constraint         Image: North C											
Implementation         [k/20] @Neb Done           Parkets         [K/20] @Rearwall         [K/20] @Rearwall         Value           Value         [K/20] @Rearwall         [K/20] @Rearwall         Value           (K/20] @Rearwall         [K/20] @Rearwall         [K/20] @Rearwall         [K/20] @Rearwall           [K/20] @Rearwall         [K/20] @Rearwall         [K/20] @Rearwall         [K/20] @Rearwall </th <th></th> <th></th> <th>[N:12] QL/L</th>			[N:12] QL/L								
Patelets         [PATUET]         Patelets         [V1]         Patelets         [V1]         Value:       [V2]         Value:       [V2]      <			[N:11] 0% [N:21] (Not Done								
Value:         Value:<	11.*	Platekts Control of Co	Perfect								
WBC [WHC]       WHC [WHC]	-	[Platelets]	[N:1] OPLATVAL] Value:								
[#9] ① [76" Ao 102 hum3           [W90] ① [76" Ao 102 hum3           [W90] ① [W90]           [W90] ① [W00]           [W90] ② [76" Ao 102 hum3           [W90] ③ [76" Ao 102 hum3           [W90] ③ [76" Ao 102 hum3           [W90] ③ [76" Ao 102 hum3           [W90] ③ [76" Ao 102 hum3           [W90] ③ [76" Ao 102 hum3           [W90] ③ [76" Ao 102 hum3           [W90] ③ [76" Ao 102 hum3           [W90] ③ [76" Ao 102 hum3           [W90] ③ [76" Ao 102 hum3           [W90] ③ [76" Ao 102 hum3           [W90] ③ [76" Ao 102 hum3           [W90] ③ [76" Ao 102 hum3           [W90] ③ [76" Ao 102 hum3           [W90] ③ [76" Ao 102 hum3           [W90] ③ [76" Ao 102 hum3           [W90] ④ [76" Ao 102 hum3           [W90] ④ [76" Ao 102 hum3           [W90] ④ [76" Ao 102 hum3           [W90] ④ [76" Ao 102 hum3           [W90] ● [76" Ao 102 hum3           [W90] ● [76" Ao 102 hum3           [W90] ● [76" Ao 102 hum3           [W90] ● [76" Ao 102 hum3           [W90] ● [76" Ao 102 hum3           [W90] ● [76" Ao 102 hum3           [W90] ● [76" Ao 102 hum3           [W90] ● [76" Ao 102 hum3           [W90] ● [76" Ao 102 hum3           [W90] ● [76" Ao 102 hum3			XXXXXXX.								
Implementation     [N:10] [mm <sup>3</sup> ]       VBC [NBC]     [Net] [max <sup>3</sup> ]       Value:     [Net] [max <sup>3</sup> ]       [Net] [max <sup>3</sup> ]     [Net] [max <sup>3</sup> ]			(N:9) 10 <sup>9</sup> /L or 10 <sup>3</sup> /mm <sup>3</sup>								
VMEC (MRC)         CMEC Value: Va			[N:10] (N:10]								
Lymphocytes (%)         Lymphocytes (%)           Lymphocytes (%)         Lymphocytes (%)	12 *	WRC .	[WBC]								
Lymphocytes (%)         Lymphocytes (%)           [Lymphocytes]         [Neil]           [Neil]         [Neil]           [Neil]         [Neil]	v.	[wsc]	10:17 UVINECVAL VVINEC								
[k*t] O (0 <sup>2</sup> k. o t0 <sup>3</sup> mm <sup>3</sup> [k*t] O (0 <sup>2</sup> k. o t0 <sup>3</sup> mm <sup>3</sup> [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )           [k:t] O (mm <sup>3</sup> )			XXXXXXXXXX								
[1:20]         [1:20]<			[N:9] 010% or 10 <sup>3</sup> /mm <sup>3</sup>								
Lymphocytes (%) [Lymphocytes]         Lymphocytes (%)           Value:         Value:           [N+7]         Value:           [N+7]         [NorDone			(N:10) 0 /mm <sup>3</sup>								
Value:           ixxxxxxxxxx.           [N.97]Not Done	1	Imphosts (%)									
хоохох. [N-97]Not Done	13.*	(zympinocynes (w) [Lympinocynes]	(N:1) [LYMPVAL]								
[N:97] QNot Done			XXXXXXXX								
gy: [*] = Item is required [✔] = Source verification required			[#:97] (0 Not Dane								
	Kej	: (*) = Hem is required (• ) = Source verification required									

GUIDEIT: Biobank (BIOBANK) - Repeating Form [frBIOBANK]								
Sample Collection Date/Time	Was subject fasting?	Sample Collected	Date/Time Processing Initiated	Date/Time Frozen	Date sent to core lab			
bank [frBIOBANK]								
Sample Collection Date/Time [Sample Collection Date/Time]			[SMPLDTM]         Req ♥ /   Req ♥ (2012-2025)           Req/Unk ♥ :         Req/Unk ♥ 24-hour clock					
Was subject fasting? [Was subject fasting?]			[PATING     [Re1]     [Re1]     [Re1]     [Re2[Unk v] / Reg/Unk v] / Reg/Unk v] (2012-3025)     [Reg/Unk v] : Reg/Unk v] 24-hour clock					
Sample Collected (Record the number of cryovials) (hidden) [Sample Collected]			Image: Constant of the second secon					
Sample Collected (Record the number of cryovials) [Sample Collected]			N3           [CpSARD02]           [IDNABL02]           /k17           [IDNABL02]           /k17           [IERNAD2]           /k17           [IERNM02]           /k17           [IERNM02] </td <td></td> <td></td>					
Date/Time Processing Initiated [Date/Time Processing Initiated]			(PRCSDTM)           Reg v         /           Reg v         /           Reg v         (2012-2025)					
Date/Time Frozen [Date/Time Frozen]			[FRZDTM]           Reg v         /           Reg v         /           Reg/Unk         v           :         Reg/Unk           :         : <td:< td="">         :&lt;</td:<>					
			Redroits . Redroits 24-hour clock					

sdGUIDEIT: Specimen consent (SPECCONS) [frSPECCONS]								
Specimen consent [InSPECCONS]								
1.* [Biorepository Sample consented] [Biorepository Sample consented]	[GBSCM] [/k:1] ©[GBSCN] Consent Date [Req v] / [Req v] / [Req v] (2012-2025) [/k:0] © No							
2. Biorepository Sample consent withdrawn [Biorepository Sample consent withdrawn]	(BeS-WTD)         [CBSSWDT]           [N: 1]         [CBSSWDT]           Withdrawal Date         [Req/Unk]           [Req/Unk]         [/ Req/Unk]							
3." DNA consented [DNA consented]	[0%10] [N:1] ∑[04cANDT] Consent Date. [Reg/Unix ] / [Reg/Unix ] / [Reg/Unix ] / [Reg [ 0 (2012-2025)]							
4. DNA-consent withdrawn [DNA-consent withdrawn]	DMACWTD]         [M:1]         [DRAWTOT]           [M:1]         [M:1]							
5. PRA consented [hidden] [RNA consented]	[PRACON]         [N:1]         [PRACON]           [N:1]         [PRACON]         [PRACON]           Consent Date         [Reg V]         [Reg V]           [N:0]         [No of ]         [No of ]							
6. RNA.consent withdrawn (hidden) [RNA.consent withdrawn]	[RMACWTD]           [N: 7]         [CRAWTDT]           Withdrawal Date           [Req V]         [Req V]           [Req V]         [Req V]							
Key: [1] - Item is required [1] - Source verification required								

	sdG #	UIDEIT: Therapy Adjust Date of therapy Hospit	alization	ACE- AF	B Beta-		Hydralazi	ine- Iva	bradine	Loop	Minera	alocorticoid	receptor	Oral thi	iazide	Valsartan/sacu	bitril Card	loversion or rat	le contro	rol for Referral for or optimization of cardiac resynchronization	Recommend exercise	training or cardiac	Provide additional HF	Any other therapy	Other
Notestanding     Notestanding       International internationa international internatione inte			in	hibitor	blocker		nitrate	s		diuretic		antagonis	st	diure	etic			a-fib		therapy	reha	D	Education	changes?	adjustment
<pre>classical control to the transmit is a set of the transmit is a se</pre>	Ther.	erapy Adjustment [rAbJUST]																							
With result of the second s	, "	[Date of therapy adjustment]	te of therapy adjustment and the state of th										Req V / Req V	/ Req 🗸	(2012-2025)										
Number of the second			the therapy adjustment(s) on this date [stADJUST2]																						
Number of the second		Hospitalization (Complete a HOSP [Hospitalization]	talization (Complete a HOSP form) stalization)									[HOSADJ] [N:1] Yes													
Max       Max         Max       M	;	Angiotensin Converting Enzyme (A	xtensin Converting Enzyme (ACE)-inhibitor																						
ANA       ANA         ANA       A	·	[ACE-inhibitor]	inhbitor]																						
State       Image: State       Image:														[N:1] 🕻	Added	1									
Image: series of the series																		[N:2] [N:3]	Stoppe Increa	ed ased					
Image: Section of the section of th																		[N: 4] 🕻	Decrea	ased					
Image: Section of the section of th																		[ACEAD	JR1						
Image: Section of the section of th																		[N-1]	Decor	ompensated HE					
Mining       Image: Section of the sectio																		[N:2] [N:2]	O Clinic	cal indication without decompensated HF rease in NT-ProBNP					
Ministration       Ministration         Ministration       Ministration																		[N: 4]	Incre	ease in NT-ProBNP					
Image: Description of the second s																		[N:5]	Other	er investigator decision					
Market in the second																			A100	o specify					
Main       Image: Comparison of the second of																		[N:6]	O Side	effects or intolerance					
Image: manual international internatinternational international international inter																		[N: 98]	Other	EADJRO]					
Mathematical state       Image: Control state       I																			Other	er specify		1			
Image: Section of the section of th																									
Image: Section of the section of th		ARB [ARB]																[ARBADJ] [N:1] [ARBCH	+G]						
NAME       Image: Second																		Yes How wa	as the th	nerapy adjusted?					
NAME       Image: Control of the state of t																		[N:1] 🕻	Added	1					
APPA       Provide and apparents         Provide and apparents       Provide and apparents      <																		[N:3] 🕻	Increa	ased					
Arrendom       Image: Section of the sect																		[N:5] 🕻	Switch	ased hed to another agent in class					
Attraction       Image: Control of the second contero of the second contero of the second contencontero of the sec																		Rationa	ale for the	ne adjustment					
Image: Section of the section of th																		[N: 1] [N: 2]	O Decor	ompensated HF cal indication without decompensated HF					
All of anti- metry       Protocol       Protocol         All of anti- metry       Protocol       Protocol         All of anti- metry       Protocol       Protocol         All of anti- metry       Protocol       Protocol         All of anti- metry       Protocol       Protocol         All of anti- metry       Protocol       Protocol         All of anti- metry       Protocol       Protocol         All of anti- metry       Protocol       Protocol         All of anti- metry       Protocol       Protocol         All of anti- metry       Protocol       Protocol         All of anti- metry       Protocol       Protocol         All of anti- metry       Protocol       Protocol         Protocol       Protocol       Protocol         Protocol       Protocol       Protocol         Protocol       Protocol       Protocol         Protocol       Protocol       Protocol       Protocol         Protocol       Protocol       Protocol       Protocol         Protocol       Protocol       Protocol       Protocol         Protocol       Protocol       Protocol       Protocol         Protocol       Protocol       Protocol <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>[N:3]</td><td>Decre</td><td>ease in NT-ProBNP</td><td></td><td></td><td></td><td></td><td></td></t<>																		[N:3]	Decre	ease in NT-ProBNP					
Image: Section of the section of th																		[N: 4] [N: 5]	O Incre	ease in NT-ProBNP BADJRO]					
Prior       Or Marine relations         Descent       Prior       Or Marine relations         Descent       Prior       Prior       Prior         Prior       Prior       Prior       Prior       Prior         Prior       Prior       Prior       Prior       Prior         Prior       Prior       Prior       Prior       Prior         Prior       Prior       Prior       Prior       Prior         Prior       Prior       Prior       Prior       Prior         Prior       Prior       Prior       Prior       Prior         Prior       Prior       Prior       Prior       Prior         Prior       Prior																			Other	er specify					
Image: Image:																									
Image: Section of the section of t																		[N:6]	Side	effects or intolerance					
Image: Construction of the second																		[14: 98]	Other	r r r specify					
Provide       Image: Imag																			A100	0					
Provide       Image: Imag	5.	Beta-blocker																[BBADJ]				1			
Open       Image: Control of Control	5. •	[Beta-blocker]																							
Provide the sector system       Image: Provide the sector system         Provide the sector system       Image: Provide the sector system         Provide the sector system       Image: Provide the sector system         Provide the sector system       Image: Provide the sector system         Provide the sector system       Image: Provide the sector system         Provide the sector system       Image: Provide the sector system         Provide the sector system       Image: Provide the sector system         Provide the sector system       Image: Provide the sector system         Provide the sector system       Image: Provide the sector system         Provide the sector system       Image: Provide the sector system         Provide the sector system       Image: Provide the sector system         Provide the sector system       Image: Provide the sector system         Provide the sector system       Image: Provide the sector system         Provide the sector system       Image: Provide the sector system         Provide the sector system       Image: Provide the sector system         Provide the sector system       Image: Provide the sector system         Provide the sector system       Image: Provide the sector system         Provide the sector system       Image: Provide the sector system         Provide the sector system       Image: Provide the sector syst																		How wa [N: 1]	as the the	nerapy adjusted? d					
The second se																		[N:2] 🔇	Stoppe	bed					
Description       Image: Constraint of the second operated o																		[N:4] 🔇	Decrea	ased					
Public decide with a components if it is in the public decide with a components if it is in the public decide with a components if it is is in the public decide with a component if it is is in the public decide with a component if it is is in the public decide with a component if it is is in the public decide with a component if it is is in the public decide with a component if it is is in the public decide with a component if it is is in the public decide with a component if it is is in the public decide with a component if it is is in the public decide with a component if it is is in the public decide with a component if it is is in the public decide with a component if it is is in the public decide with a component if it is is in the public decide with a component if it is is in the public decide with a component if it is is in																		[BBADJ	IR]						
Digital control       Contro       Control       Control																		Rationa [N:1]	ale for the	ne adjustment ompensated HF					
Provide       Provide																		[N:2]	Clinic	cal indication without decompensated HF					
Dipute specty       Investige         Investige       Investige																		[N:4]	Incre	ease in NT-ProBNP					
Digital       Image: Constraint of the second consecond consecond constraint of the second constraint of t																		[N:5]	Other	auxoj er investigator decision					
Digital       Image: Control of the second of																			A100	n speciny O					
Digital       Image: Control of the second of																		[N:6]	◯ Side	effects or intolerance		I			
Digodin     International intern																		[N: 98]	O LOBB	BADJRO1					
Dippoin       Image: Control of the second of																			Other A100	er specify 10					
Yes       was the therapy adjusted?         (N 1)       (N 2)         (N 2)       (N 2)																									
Yes       was the therapy adjusted?         (N 1)       (N 2)         (N 2)       (N 2)	-	Digoxin [Digoxin]																[DIGADJ] [N:1] [DIGCH	iG]						
[N:2]       Operation         [N:4]       Operation																		Yes How wa	as the th	nerapy adjusted?					
[N:3]       Oncreased         [N:4]       Operating         [N:5]       Switched to another agent in class         [Dicacon]       Decrease intervention         Rationale for the adjustment       [N:1]         [N:2]       Operating         [N:2]       Decrease intervention         [N:2]       Decrease int-Probate         [N:4]       Operating																		[N:2]	Stoppe	ed					
[N:3]       Ownthed to another agent in class         IDECADE       Rationale for the adjustment         Rationale for the adjustment       [N:1]         Decompensated HF       [N:2]         [N:2]       Decompensated HF         [N:3]       Decrease in NT-PrOBNP         [N:4]       [Increase in NT-PrOBNP         [Increase in NT-PrOBNP       [Increase in NT-ProBNP         [Increase in																		[N:3] 🔇	Increa	ased					
Bationale for the adjustment         [N:1]       Decrease INT-Proble         [N:2]       Cinical indication without percentional percentipercention percentipercentional percentional percentional percente																		[N:5] 🤇	Switch	hed to another agent in class					
[N:2]       Obcrease in NT-PORNP         [N:4]       Obcrease in Numericano decision         [N:4]       Obcrecol																		Rationa	ale for the	ne adjustment					
(N.4)       Olicorase in NT-POBNP         (N.4)       Olicorase in NT-PoBNP         (N.4)       Olicorase in NT-POBNP         Other investigator decision       Other investigator decision         Altoo       Altoo         (N.8)       Colcatool         Other specify       Other specify         Other Specify       Other Specify         Altoo       Altoo																		[N: 2]	Clinic	cal indication without decompensated HF					
(N:3)       Other Investigator decision Other specify         AT00       (N:4)         (N:4)       Other Investigator decision Other Specify         (N:4)       Other Investigator decision Other         (N:4)       Other Investigator decision Other         (N:4)       Other         (N:4)       Other         Other       Other																		[N:4]	Incre	ease in NT-ProBNP					
Image: Constraint of the specify       Image: Constraint of the specify       Image: Constraint of the specify       Image: Constraint of the specify       Image: Constraint of the specify       Image: Constraint of the specify																		[N:5]		SADJRO]					
[N:6]     O     Side effects or intolerance       [N:8]     O[IOGADRRO]       Other specify       At00																			Other	er specify					
[N:90]         [Otorabo]           Other         Other           Other specify         A100																									
Other specify A100																		[N:6] [N:98]	O Side	effects or intolerance IGADRO]					
A100																		,	Other	er specify					
Indexentional         Indexentional           Indexentional         Indexentional																			A100	0					
	1.	Hydralazine-nitrates																[HNADJ]							



	(N 4) OIncrease in NT-ProBNP			
	(hes) (IHZADJRO) Other investigator decision			
	Other specify A100			
	[Ke] ○ Site effects or intelenance [Keaj ○ OfHZARD]			
	[N 98] CITHLADRO) Other Cither specify			
	A100			
12. Vakartar/socibit# · [Vakartar/socibit#]	[LCZADJ] [h:1] [[LCZCH6]			
	Yes Now was the therapy adjusted?			
	Yeow was the therapy adjusted? (µ 1) ②Added (µ 2) ②Stopped			
	(N.3) © Increased (N-4) © Decreased			
	[k:s] OSWIChed to another agent in class [LCZADJR]			
	Rationale for the adjustment (N: 1) Decompensated HF			
	(h ≥ ) ① Clinical indication without decompensated HF (h 3) ② Decrease in NT-ProBNP			
	(h: 4) ① Increase in NT-ProBNP (h: 5) ① [LCZADJRO]			
	Cither investigator decision Other specify A100			
	[N 6] [N] Side effects or intolerance			
	[ <i>h v</i> ] (CloccARRO) ( <i>h v</i> ] (CloccARRO) Other			
	Other specify A100			
13. Cardioversion or rate control for a-fib				
1.1. Cardioversion or rate control for a-tip (Cardioversion or rate control for a-tip) (Cardioversion or rate control for a-tip)	[RCADJ] [N:1] _[RCADJR] Yes			
	( <i>n</i> + 1) Ves     Risionale for the adjustment     ( <i>n</i> + 1) ①Decompensated HF     ( <i>n</i> + 2) ⑦Decompensated HF			
	(N:3) ODEcrease in NT-ProBNP			
	(N-4) © Increase in NT-ProBNP (N-5) © (IRCADIRO] Other Investigator decision			
	Other specify			
	A100 [ <i>N</i> 6] ① Side effects or intolerance			
	(R6) Use inclusion investing (N89) (Clockabo) (N99) (Clockabo) Other			
	Other specify A100			
14 Determined for or antientration of another investmentation between				
14. Referral for or optimization of cardiac resynchronization therapy ✓ [Referral for or optimization of cardiac resynchronization therapy]	[CRTAD] [N:1] [[CTADR] Yes			
	Rationale for the adjustment (N: 1) Decompensated HF			
	[ <i>h</i> :2] □Clinical indication without decompensated HF [ <i>h</i> :2] □Clinical indication without decompensated HF			
	(N-4) Charasses in NT-ProBNP (N-5) CERTADAROJ Other investigator decision			
	Other investigator decision Other specify A100			
	[N 6]  (N 6]  (N 6]  (N 6]  (N 6)  (			
	(he) USAR INCOMENCE (he) () [OCRTADOD] (he) Other			
	Other specify A100			
15. Recommend exercise training or cardiac rehab				
Recommend exercise training or cardiac rehab     [Recommend exercise training or cardiac rehab]	[EXERCZ] [k:1] [[EXERCZR] Yes			
	Image: The second se			
	(N 2) Clinical Indication without decompensated HF (N 3) ODecrease in NT-ProBNP			
	[Red] Cincrease in NT-POBNP [Red] CINCRERO]			
	Other investigator decision Other specify			
	A100 [Ne3]  [N] Side effects or intolerance			
	(N:98) O(EXERCRO) Other			
	Other specify A100			
16. Provide additional HF Education				
16. Provide additional HF Education Provide additional HF Education)	[HFED] [N:1] [HFEOR] Ves Rationale for the adjustment			
	[N:1] Occompensated HF			
	(N-2) Clinical indication without decompensated HF (N-3) Clinical indication without decompensated HF (N-3) Clinical indication without decompensated HF			
	(N-4) © Increase in NT-ProBNP (N-5) © (₩ERDO) Other investigator decision			
	Other investigator decision Other specify A100			
	( <i>h</i> , <i>b</i> )			
	[ke3]     [ClothErEO]       [kv3]     [Clother       Other     Other			
	Other specify A100			
1 1 2 1 Did the subject have any other therany channes?				
17." Did the subject have any other therapy changes? (Any other therapy changes?)	[Unit Here] [htt] ©Yes [htt] ©No			
Other adjustment How was the therapy adjusted?	Into Carlos Rationale for the adjustment			
8. Inter adjustment Entry (rsADJUST3)				
--	--	--	--	--
1 Other adjustment (Other adjustment)	[OTHAD.] A 100			
2 How was the therapy adjusted? [How was the therapy adjusted?]	DTHCHO           [N:1]         [Dadad           [N:2]         [Dataped           [N:3]         [Datareased           [N:4]         [Decreased           [N:4]         [Decreased           [N:4]         [Decreased           [N:4]         [Decreased           [N:4]         [Decreased           [N:4]         [Decreased]			
3 Rationale for the adjustment [Rationale for the adjustment]	ICHADBIN         (I/: 1)       OEcompensated HF         (I/: 2)       OEcompensate HF         (I/: 2)       OEcompensate H			

dGUIDEIT: Adherence Case Review (ACR) [frACR]	
Adherence Case Review [stACR1]	
1.*         Dd the Adherence Committee Reviewer adjudicate this case?           Did the Adherence Committee Reviewer adjudicate this case?	[aceboxe] [N:1]Q*us [N:0]QNo

dGUIDEIT: Adherence Review Findings (ARF) [frARF]			
Adherence Review Findings (stARF1)			
	[A4CRWR] [Nr 1] 0 [Nr 2] 0 [Nr 2] 0 [Nr 2] 0 [Nr 2] 0 [Nr 4]		
	Image: The Subject and Subject is non-compliant with medications         Image: The Subject is non-complicant with medin medications		
* Clinical Operations contacted site to discuss issue [Clinical Operations contacted site to discuss issue]	[COTALKD] [N: 1] ○ [¢ContactCluery] Yes Contact method [TALKWPPA] [N: 1] □ Contacted/ enailed the PI about concerns [TALKORY] [N: 1] □ Issued a query [N: 0] ○ No		
Adherence Committee contacted site to discuss issue     [Adherence Committee contacted site to discuss issue]	[AH¢TAIXO] [P(:1] Q)*s [P(:2] Q)Ho		
Vould the reviewer like to discuss on an Adherence Committee Cal? Vould the reviewer like to discuss on an Adherence Committee Cal	[AcFCouDP] [N 1] 0] Ves [N 2] 0] No		
Com	nments		
·   omments from Adherence Review Entry [rsARF2]			
1 Comments	[ACCOMMT]		
[Comments]	A200		
Key: (*) = Item is required [*] = Source verification required			

sdGUIDEIT: Assessments (ASMT) [frASMT]			
Vote: If subject had an AE, SAE or extended care facility admission, complete the appropriate form in the CAS visit. [sIASMT1]			
1. Were local labs performed? (If yes, please complete LABS form) Were local labs performed? [ Were local labs performed?]	(ST07A82)           (N 1)         ∑ Ves           (N 2)         ∑ Subject rotuned		
2. <sup>*</sup> Were protocol required biological samples collected? (If yes, please complete BIOBANK form)  (Were protocol required biological samples collected?)	[4010002] [0:1] Ø Yes [0:2] Ø We [0:2] Ø Subject refused		
3.* Was local NT-proBNP measured? (If yes, please complete PROBNP form) (Question only expected for biomarker guided arm) (Was local NT-proBNP measured?)	(N17PROMS)           (N17)           (N20)           (N		
<ul> <li>4.* Has the subject had an inplatient hospitalization, outpatient procedure or emergency department visit? (If yes, complete new HOSP visit)</li> <li>(Has the subject had an inplatient hospitalization, outpatient procedure or emergency department visit? )</li> </ul>	(HOSEADAMT) [N: 1] © YKS [N: 2] © NO		
<ul> <li>D dt the subject have an echo performed?</li> <li>(Applicable for Echo Sub-Stuby Participating Sites ONLY. Expected answer of No. if not participating.)</li> <li>[Subject have an echo performed since the last visit]</li> </ul>	[K:1]         [CEHOSHP]           Ves         Date submitted to DCRI           [K:7]         [CEHOSHP]           [K:7]		
• Was therapy adjusted? (If yes, please complete ADJUST form) • [Was therapy adjusted?]	[PHNDJ]         [N:1]       [Versen]		
Specify reason already at maximally tolerated therapy     [Specify reason already at maximality tolerated therapy]	(MAXTLDS) A200		
Resource use [stASMT2]			
g *       Has the subject been seen as an outpatient by a clinician?]         [Has the subject been seen as an outpatient by a clinician?]         Key: [*] - Item is required [*] - Source verification required	[OPTVST]         [N: 1]       [OPTVSTV]         Yes       Specify the number of cardiovascular visits         [OPTVTKV]       Specify the number of non-cardiovascular visits         [N: 0]       [No		
cy. L) = item is required (▼) = source verification required			

S	sdGUIDEIT: Method of Contact (CONTACT) [frCONTACT]		
м	Method of Contact [IrCONTACT]		
1.	Was this visit performed? [Vait performed?]	[10:37]         ***         7: Source of visit           ***         7: Source of visit         ***           ***         7: Source of visit         ***           (**:0)         7: Source of visit         ***           ***         7: Source of visit         ***           ***         7: Source of visit         ***           ***         7: Source of visit         ****           ***         7: Source of visit         ************************************	
	Delete visit - site created the visit by accident [hidden] (Delete visit]	[DELETVST] (№ 1) □Yes	
	$\frac{1}{2}$ = 1 tem is remained [ $\mathbf{v}$ ] = Source verification remained		

sdGUIDEIT: End of study (EOS) [frEOS]		
End of study [rEOS]		
1.* Date of last study contact [Date of last study contact] [Date of last study contact] [Date of last study contact]		
2.* Status at end of contact V [Status at end of contact]	[M:1]       Didd, please complete DEATH form         [N:1]       Completed protocol         [N:1]       Stablect test for follow-up         [N:1]       Stablect withdraw consent for study participation         [N:4]       Stablect withdraw from the study by site investigator         [N:4]       Stablect withdraw from the study by site investigator         [N:4]       Received a procedure with effect on NT-Pro-BMP (e.gUNAD, Dialysis, Heart Transplant)	
Key: [1] - Item is required [ ] - Source verification required		

sdGUIDEIT: Death (DEATH) [frDEATH]				
Desth (frDEATH)				
1.* Date and time of death	[DEADDTM]			
[Date and time of death]	Req/Unk v / Req/Unk v / Req v (2012-2025)			
	Reg/Unk v : Reg/Unk v 24-hour clock			
2* Was the subject hospitalized or was at an extended care facility at the time of death. (If yes, complete a HOSP or EXTCARE form)				
2. Was the subject hospitalized or was at an extended care facility at the time of death. (If yes, complete a HOSP or EXTCARE form) (Hospitalized at time of death)	(N:1) QYes			
	(N:0) ONO			
	(N: 99) Q Unknown			
	[WITNES]			
a Was the death witnessed? Was the death witnessed]	In the set of the set			
	(N:99 Q Unknown			
4. Was an autopsy performed? [hidden] [Was an autopsy performed?]	[Auropsy] [h:1] QVss			
(ma an usup) jero meaj				
	(N:99) Ulrknown			
5. Primary cause of death (hidden) [Primary cause of death]	[DEATHEAU] (h:1) @Heart failure			
	( <i>n</i> : 1) ↓ mean torue ( <i>n</i> : 2) ↓ Sudden cardiac death			
	( <i>n</i> :2) Obter and/occular			
	(N:4) ON-cardiovascular			
	(N:99 OUnknown			
6* Was an autopsy performed?				
6. Was an autopsy performed? (Autopsy performed)				
<ul> <li>Instant and the second s</li></ul>	(h: 1) Q(AUTFSOTL) Yes			
	Record relevant findings from the autopsy			
	A200			
	(N: 0) 🔘 No			
	[N: 99] O Unknown			
7.* Primary cause of death	[DEATHCA2]			
[Primary cause of death]	/N:1) O Heart Failure/Cardiogenic Shock			
	(N:2) Acute Coronary Syndrome/ MI			
	[N:3] [DTHRSOC2]			
	Other cardiovascular Other cardiovascular specify			
	A200			
	[N-1] (DTHESNC2] Non-cer divussular			
	Non-cardiovascular specify			
	A200			
	[N-5] Sudden Cardiac Death			
	(N: 9) Unknown/ Undetermined			
8. Trigger number Trigger somebor				
[Trigger number]	A100			
What were the relevant medi	ical events leading up to the death			
9.				
NARRATIVE Entry [rsDEATH2]				
9.1* What were the relevant medical events leading up to the death (e.g., hospitalized, at home, palliative care, contributing co-morbidities, witness account)?	[DEATNARR]			
[What were the relevant medical events leading up to the death]	A200			
(*) = Item is required (*) = Source verification required				

sdGUIDEIT: Echo trigger form (ECHOTRG) [frECHOTRG]		
cho trigger form [stECHOTRC1]		
1.* Tracking Number [Tracking Number]	[ECOTRONM] A50	
2.* [Visit]	[EcHowist]           [N:1]         ③Bassine           [N:2]         ③12-Month           [N:3]         ③[EcHoward]           Unscheduled         [N:1]           [N:1]         ③[EcHoward]           [N:1]         ④[Echoward]           [N:1]         ④[Echoward]           [N:1]         ④[Echoward]           [N:1]         ④[Echoward]           [N:1]         ④[Echoward]	
3.* Was a 2D Etho Digheev Protocol completed for this visit? [Was a 2D Etho Digheev Protocol completed for this visit?]	[TecobeCo] [/k::1] ©Yes [/k::2] ⊙ No	
4.* Wes a Tomize Etho eCBF completed for this visit? (Was a Tomize Echo eCBF completed for this visit?)	IOMEC         0           (h: 1) © Yes         (h)           (h: 2) © No         (h)	
Key: [1] = Item is required		

sd	GUIDEIT: FINDINGS (FNDGS) [frFNDGS]				
Hen	dynamic Findings; [stFNDGS1]				
	Systolic BP (Systolic BP)	[SYSBP2DD] /h:1] ①[SYSBP2DR]			
		/0:1/ USTSB/ZUNJ   XXXXXXXXX			
		(N-96) ONA			
2.*	Disstolic BP (Disstolic BP)	[DIABG2DD]			
		/0.17 (01/08/208) xxxxxxxx			
		(N:96) QNA			
3.*	Heart Rate (Heart Rate)	[HRT2DD] [N:1][HRT2DR]			
		XXXXXXXX			
		(N:96) [NA			
Mac	hine Settings: [stFNDG52]	·			
4.*	Nyquist Limit (Nyquist Limit)				
		XXXXXXXX.			
		[N:96] () NA			
5.*	Depth (Depth)				
	(rebui)	(h:1) (DEPTHR)			
		[N:96]NA			
6.*	Color Gain [Color Cain]				
	(coor can)				
		[N:96] ONA			
7.*	Frame Rate [Frame Rate]	[FRMRTD]			
	[Iuaua kara]	[N:1] (D[FRMRTR] x00000000.			
		(N:96) NA			
8.*	AV Regurg (AV Regurg)	[AVREGURG]			
	[AV Regurg]	(AVECURC) [0:1] @None [0:2] @Trival			
		(n2) (Mid			
		(N-3) Qwiid (N-4) Qwidderate			
		(n.s.) Osevere (n.s.) ONA			
- ·	N Renua				
9.	MV Regurg (NV Regurg)	(MVRSCURC)           (M.1)         (Mone           (M.2)         (Trivial           (M.3)         (Moderate			
		N22 OTTVial			
		1N-3 0 Whid N-4 0 Mederate			
		(N:5) Severe			
		(K-94) QNA			
10.*	TV Regurg (TV Regurg)	[TV#EGURG] (V11 ONono			
		(h:1) ONone (h:2) OTrivial			
		(N:3) Mild			
		[ <i>n.4</i> ] @Moderate [ <i>n.5</i> ] @Severe			
		[R:96] ONA			
11.	Visual LVEF [Visual LVEF]				
	(Visual LVEF)	(N:1) VISLEFOR XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX			
		(N:96) ONA			
12.*	Distolic Fxn Score (Disstolic Fxn Score)	(DA7XS0R)           (P0.2)           (P1.0)           (P1.0) <td< th=""></td<>			
	[Liastolic +xn Score]				
		(m2) 02			
		(N:3) (3or 4			
		(N-9) ONA			
13 *	Palm Vein Dom [Pulm Vein Dom]	[PUVNDOM]			
1.2.	[Pulm Vein Dom]	[PULVNDOM] [htt] [] Systole			
		[/0:2] © Distole 0:2] © Estudocal			
		(h/s) CEquivocal (h/sec) NA			
14.*	Out DV For				
	[rmai ka i xu]	1 <i>N</i> :1/ QNORMA <i>N</i> :21 ONITIN' IMAGED			
		Unit O'Normal  (P13) O'Normal  (P13) O'Nordardely impaired			
		[11-4] OSeverely Impaired [10:56] ONA			
-	Normal Article Control of Control				
15.	Thrombus (Thrombus)	THROMASS]         [///www.sci.ent/line           [//way]         @Masent           [/way]         @LTHAMASLT			
		(N-2) OAbsent			
		/ Nr:1) (D]THRMMSLT] Present			
		Present If present, thrombus type			
		(n ≈ 2) (n ≈ 3) (n ≈ 1) (n ≈ 1) (n ≈ 2) (N ≈			
		[ <i>N</i> −3] ◎RA [ <i>N</i> −4] ◎RV			
		Other ThrombusOther (specify)			
		A200			
16.	2D Echo Digivi	ew comments			
	Echo Digiview comments Entry [rsFNDGS3]				
16 1	* 2D Echo Diglview comments [2D Echo Diglview comments [2D Echo Diglview comments]	[DIGCOMTD]			
1	[2D Echo Digiview comments]	<i>lle:1</i> □ (Diaconts) Yes			
		105 A200			
		[ <i>II:0</i> ] © No			
_	2D Echo Digiview a	additional findings			
1.7					

2D Echo Digiview additional findings Entry [rsFNDG54]		
17.1 <sup>°</sup> [2D Echo Digiview additional findings] [2D Echo Digiview additional findings]	[Doi-GFNBOD]	
Key: [*] - ttem is required		

AUGULDELLE Z-D MEASUREMENTS (MEAS2D) TITMEAS201				
dGUIDEIT: 2-D MEASUREMENTS (MEAS2D) [frMEAS2D]		LVPW Dias Thick	IVS Dias Thick	LV Mass
/ Mass ASE Entry [rsMEAS2D1]		[[]][]][]][]][]][]][]][]][]][]][]][]][]		
LVID Dias Diam         LVID Dias Jiam           [LVID Dias Jiam]         [ht 1] ① [LVID OR]           [xvox)         [kvox)           [xvox)         [ht 2] ① [NA				
.2* LVPW Dias Thick [LVPW Dias Thick]		[LVPWDTD] [//: 1] [LVPWDTR] [XXXXXXXXXX [/:: 96] [VA		
3' IVS Dias Thick [IVS Dias Thick]		[IVSDTD] [N:1] [VISDTR] [N:90] [VIA		
.4° [LV Mass [LV Mass]		[LVM0] [N:1][LVMR] [N:9][VAA		
		LVID sys dimen		
eft Ventricle: Sys Dimen Entry [rsMEAS2D2]				
1,* [LVID sys dimen]		[LVIDSDD] [N:1] [][LVIDSDDR] [XXXXXXXXX [N:96] [] NA		
		LVOT sys dimen		
VOT Dimen Entry [rsMEAS2D3]				
,1* [LVOT sys dimen ]		[LVOTSDD] [N:1] ①[LVOTSDDR] [N:96] ②NA		
		4ch LV Length		
i.   Ich LV Length Entry [rsMEAS2D4]				
(4ch LV Length (4ch LV Length (4ch LV Length)		[LV4EDDDD] [N:1] [] [LV4EDDDR] [X0000005.		
		[N:96] ONA		
		2ch LV Length		
ch LV Length Entry [rsMEAS2D5]				
.1* [2ch LV Length [2ch LV Length]		[LV2EDDDD]		
[2ch LV Length]		(№ 1) ○[L¥ZEDDOR] (№ 96) ○NA (№ 96) ○NA		
LV Dias volume	LV Sys volume	2D Stroke vol	Ejection Fraction Heart Rate	Card Out
V EF Biplane Entry [rsMEAS2D6]				
s,1* [LV Dias volume [LV Dias volume]		[IveDvD] [N:7] [VeDvR] [N:96] [VA		
5.2* [LV Sys volume [LV Sys volume]		[LVESVD] [N:1] [][LVESVR]		
6.3* 2D Stroke vol		XXXXXXXX		
6.3" 2D Stroke vol [2D Stroke vol]		[N ≠8] [N ≠8] [N-1] [Sv200] [N-1] [Sv208]  xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx		
		[N ≠ 8] [N + 8] [N + 1] [S + 200] [N + 1] [S + 2008] [N + 9] [N + 9] [N + 9] [N + 9] [N + 1] [Uver rp] [N + 1] [Uver rp] [N + 1] [Uver rp]		
5,4' Ejection Fraction [Ejection Fraction]		IV 2000         IV 2000           IV 100         [SV200]		
22 Stroke vol     22 Stroke vol     2     25 Stroke vol     2     25 Stroke vol     2     25 Stroke vol     2     25 Stroke vol     2     25 Stroke vol     2     25 Stroke vol     25     25 Stroke vol     25 Stroke vol		IN #20         NA           (SY2DD)         (N12)           (N12)         (SY2DR)           (N12)         (IVBEFD)           (N12)         (IVBEFD)           (N12)         (IVBR)		
4         Ejection Fraction           [Ejection Fraction]         5           5         Heart Rate (Heart Rate)		IV set@         VXXXXX           [SYZDD]         [SYZDD]           (N1)         [SYZDR]           XXXXXXXXX         [New set]           (N1)         [LVBETR]           (N2)         [NA           (N2)         [NA		
4     Ejection Fraction       [c]isection Fraction]		IN #20         NA           (SY2DD)         (N12)           (N12)         (SY2DR)           (N12)         (IVBEFD)           (N12)         (IVBEFD)           (N12)         (IVBR)		
4         Ejection Fraction           [f]section Fraction]		Image: Second		
		IV set@         VXXXXX           [SYZDD]         [SYZDD]           (N1)         [SYZDR]           XXXXXXXXX         [New set]           (N1)         [LVBETR]           (N2)         [NA           (N2)         [NA		
		Image: Second		
4*         Ejection Fraction           5*         Heart Rate           (Heart Rate)		Image: Second		
Epection Fraction     [Fjection Fraction]      Heart Rate     [Fjection Fraction]      Heart Rate     [Reart Rate]      Heart Rate     [Gard Out     [Card Out]      [LA Sys Area 4ch Entry [rsMEAS2D7]      [LA Sys Area 4ch]      Avol Biplane: LA vol Entry [rsMEAS2D8]		Image: Second		
4         Ejection Fraction [Ejescion Fraction]           5 <sup>*</sup> Iteart Rate [Ejescion Fraction]           6 <sup>*</sup> Card Out [Card Out]           6 <sup>*</sup> Card Out [Card Out]           7         IA Sys Area 4ch Entry [rsMEAS2D7]           1 <sup>*</sup> [LA Sys Area 4ch]           2         Aval Biplame: LA vol Entry [rsMEAS2D8]		Image: Constraint of the second sec		
4         Ejection Fraction [Ejescion Fraction]           5 <sup>*</sup> Iteart Rate [Ejescion Fraction]           6 <sup>*</sup> Card Out [Card Out]           6 <sup>*</sup> Card Out [Card Out]           7         IA Sys Area 4ch Entry [rsMEAS2D7]           1 <sup>*</sup> [LA Sys Area 4ch]           2         Aval Biplame: LA vol Entry [rsMEAS2D8]		Image: Second		
4         Ejection Fraction [[s]ection Fraction]           5 <sup>*</sup> Heart Rate [Heart Rate]           6 <sup>*</sup> Card Out [Card Out]           6 <sup>*</sup> Card Out [Card Out]           7         LA Sys Area 4ch Entry [rsMEAS2D7]           1 <sup>*</sup> LA Sys Area 4ch]           2         A vol Biplane: LA vol Entry [rsMEAS2D8]           1 <sup>*</sup> LA volume]		Image: Constraint of the second sec		
		Image: Second		
.4*       Ejection Fraction         .5*       Heart Bate         .6*       Card Out         .6*       Card Out         .6*       Card Out         .1       Heart Bate         .1       File Antime         .1       Entry [rsMEAS2D7]         .1       LA Sys Area Ach Entry [rsMEAS2D7]         .1       LA Sys Area Ach Entry [rsMEAS2D7]         .1       LA OU Entry [rsMEAS2D8]         .1       LA vol Entry [rsMEAS2D8]         .1*       LA Sys Area 4ch Entry [rsMEAS2D8]		Image: Second second		
4*       Ejection Fraction [[stpection Fraction]         5*       Heart Rate [[stret Card Out]         6*       Card Out [Card Out]         6*       Card Out [Card Out]         1*       LA Sys Area 4ch Entry [rsMEAS2D7]         1*       LA Sys Area 4ch Entry [rsMEAS2D7]         1*       LA Vol Biplame: LA vol Entry [rsMEAS2D8]         1*       LA volume]         1*       LA volume]		Image: Second		

10.1	(RV Basal Wath)	[Rv1 Dock]         [Rv1 Dock]           xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
	RV Mid \	Width
11.		
RV M	lid Width Entry [rsMEAS2D11]	
11.1	(RV Mid Width)	[RV10M00]         [RV10M00]           x         x           x     <
	RV Long I	Length
12.		
RV L	ong Length Entry [rsMEAS2D12]	
12.1	(RV Long Length)	[RVIDLD0] [k:1][RVIDL0R] 
Key	: [*] - Item is required	

sdGUIDEIT: M-MODE and DOPPLER MEASUREMENTS (MMDOP) [rmMDOP]				
	TAPSE			
1.				
RV TAPSE Entry [rsMMDOP1]				
1.1 * TAPSE (m) [TAPSE]	[TAPSED] [/k1] ©[TAPSER] [x0000000. [/k90] © NA			
Ti Jet Vel	Sys Press TV			
2.				
RA PA Sys Press Entry [rsMMDOP2]				
2.1 T Jet Vel [T Jet Ve]	[Pertret_D] [№1] 0 [Pertret_R] [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [			
2.2 <sup>(1)</sup> Sys Press TV [Sys Press TV]	[Pr05P0]           [N/1]         [CP05P0]           xxxxxxxxxx         xxxxxxxxx           [N/2]         [CN0500000000000000000000000000000000000			
	Pk E Vel			
3.				
Mitral Valve: Peak E Vel Entry [rsMMDOP3]				
3.1. <sup>1</sup> [PK E Vel [PK E Vel]	[PEAKED] [N+7] ○ [PEAKER] [N0000000. [N/94] ○ NA			
	Pk A Vel			
4.				
Mitral Valve: Peak A Vel Entry [rsMMDOP4]				
4.1" (*A.Vel [PF.A.Vel]	[PEAKAD] [/k:1] © [PEAKAR] [x0000000, [/k:90] © NA			
	Decel Time			
5.				
MV Decel Time Entry [rsMMDOP5]				
5.1 <sup>(Decel Time</sup> (Decel Time)	[MMOTD] [№1] © [MMOTR]  ∞0000000. [№99] © NA			
	Septal TDI é			
6.				
Septal TDI é Entry [rsMMDOP6]				
6.1 <sup>*</sup> Septal TDI é (Septal TDI é)	(SEPTION) [/k1] © (SEPTION) [x000000. [/k90] © NA			
	LVOT TVI			
7.				
LVOT Forward Flow Entry [rsMMDDP7]				
17.1 UV TVI [UV07 IV]	[PV1D]           [0x1]         [DT018]           [xxxxxxxx.           [0x0]         [DNA			
	trivă Ani			
Key: [*] = Item is required				

sdGUIDEIT: Tomtec (TOMTEC) [frTOMTEC]	
Tomtec [frTOMTEC]	
1. <sup>*</sup> [Apical 4-Ch Frame Rate [Apical 4-Ch Frame Rate]	[A4CFR0] [/::1]
2.* [Apical 2-Ch Frame Rate [Apical 2-Ch Frame Rate]	[A2CFR0] [/1:1] ○[A2CFR] [x0000000. [/1:9] ○[NA
3.* Apical 3-Ch Frame Rate [Apical 3-Ch Frame Rate]	[AGCFR0] [//:7] ○ [AGCFR] [//:0] ○ (MACFR] [//:0] ○ [
Global Longitudinal LV strain [stTOMTEC1]	
4. <sup>*</sup> [Apical 4-Ch Global Long LV [Apical 4-Ch Global Long LV]	[A4C6LLVF] [/::] [AC6LLVF] xxxxxxxxx. [/::%] [] NA
5. <sup>*</sup> [Apical 2-Ch Global Long LV [Apical 2-Ch Global Long LV]	[A2CGLVB]  /::1) □ [A2CGLVB]  /::9) □ NA
6.* [Apical 3-Ch Global Long LV] [Apical 3-Ch Global Long LV]	[ASGULV9] //// ∑ A3-GULV8] /// ∑ (xxxxxxx) /// % Q MA
Longitudinal RV strain [stTOMTEC2]	
7." [Basal 4-Ch Long FV [Basal 4-Ch Long RV]	[B44:9760]         [0:1]
8.* [Mid 4-Ch Long RV]	DMLEVKD)         [////]           ////]         [////]           ////]         [///]           ///]         [///]           ///]         [//]
9.* [Apical 4-Ch Long RV] [Apical 4-Ch Long RV]	[A44:9780]           /№ 7.]         ○A44:9780]
	Tomtec comments?
10.	
Tomtec comments Entry [rsTOMTEC3]	
10.1 <sup>*</sup> [Tornte: comments? [Tornte: comments?]	[TTCOMTND] ///: 1) OTTCOMTNS] // Yes // A200 ///: 0) No
Key (3) Annu is sensioned	Ind A
Key: [*] – Item is required	

sdGUIDEIT: frSIGN (SIGN) [frSIGN]	
frsign [frsign]	
1.* Casebook Ready for Signature (Casebook Ready for Signature)	(PISIGN) (k:1) []]Yes
Key: [*] = Item is required [*] = Source verification required	

InForm Special Property	Property Type	Data Object RefName	Data Object Path RefName
Screening	Visit	evSYSSCR	evSYSSCR
Enrollment	Visit	evSYSENR	evSYSENR
Screening	Form	frSYSSCR1	evSYSSCR.frSYSSCR1
Enrollment	Form	frENRSYS2	evSYSENR.frENRSYS2
Patient Identification	Form	frDEM	evBLN.frDEM
Study Completion	Form	Unassigned	Unassigned
Reg Docs	Form	Unassigned	Unassigned
Visit Report	Form	Unassigned	Unassigned
Initials (Screening)	Item	SUBJINIT	evSYSSCR.frSYSSCR1.SUBJINIT
DOB (Screening)	Item	Unassigned	Unassigned
Screening date (Screening)	Item	Unassigned	Unassigned
Patient No. (Enrollment)	Item	SUBJID	evBLN.frDEM.SUBJID
Initials (Patient Identification)	Item	Unassigned	Unassigned
Completion status (Study Completion)	Item	Unassigned	Unassigned
Drop out reason (Study Completion)	Item	Unassigned	Unassigned
DOV (Date of Visit)	Item	EVALUDT	EVENTEURDDE EVALUDT EVMCSZEURDDE EVALUDT EVMCSTEURDDE EVALUDT EVMCNTEURDE EVALUDT EVMCNTFDDE EVALUDT EVMCNZEURDDE EVALUDT EVMCNZEURDDE EVALUDT EVMCNTFURDE EVALUDT EVMCNTEURDE EVALUDT EVMCNTEURDE EVALUDT EVMCNTEURDE EVALUDT EVMCNTEURDE EVALUDT
Randomization field (Randomization)	Item	Unassigned	Unassigned
(			